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ABSTRACT 
Rating scales and diagnostic instruments have become increasingly important tools in 
psychiatric care over the past several decades. Using these standardized tools to collect 
information and evaluate patients enables streamlined evidence-based diagnosis and 
assessments of functioning. This thesis revolves around the Children’s Global Assessment 
Scale (CGAS), a widely used rating scale designed to measure how a child functions 
psychosocially in daily life.  
In Paper I, the inter-rater reliability (IRR) and accuracy of CGAS ratings among 
untrained raters (n=703) were assessed in a large clinical setting. The untrained raters 
scored case vignettes significantly higher than the gold standard established by experts. 
The IRR in terms of intra-class correlation coefficient (ICC) was 0.73. Social workers and 
psychologists were significantly more likely to have overall aberrant ratings than medical 
doctors. The results suggest that reliability and accuracy is moderate when CGAS is used 
in a clinical setting with untrained raters. 
In Paper II, two training methods to improve CGAS ratings were evaluated. Untrained 
raters (n=648) were randomised to training either by a CD-ROM or in a seminar. In 
addition, 55 raters formed a non-randomised comparison group. There was no significant 
difference between the two training groups at the 12-month follow-up. The untrained 
comparison group improved at the same order of magnitude as the training groups. The 
ICCs at baseline and at end-of-study were 0.71/0.78 (seminar), 0.76/0.78 (CD-ROM), and 
0.67/0.79 (comparison). These results speak in favour of using the less resource-
demanding computer-based training. However, the overall training effect was too small to 
be clinically relevant. Future evaluations of training methods should include a control 
group to control for unspecific learning effects. 
Registration of CGAS ratings in the clinical database Pastill was initiated at the 
completion of the training activity carried out for Paper II. This enabled a study on the 
effectiveness of child psychiatric treatment by examining the change in psychosocial 
functioning as measured by CGAS described in Paper III. The change in CGAS ratings 
between intake and case closure was investigated for 12,613 patients. CGAS improved 
during the course of treatment across all diagnostic groups. In the mood disorder group, 
several psychotherapies were associated with improved outcome whereas medication was 
not. In the Attention-Deficit Hyperactivity Disorder (ADHD) group, medication with 
central stimulants was not associated with improvement. Treatment-as-usual was found to 
be less effective than clinical trials have indicated, particularly for the ADHD group, 
suggesting that results from clinical trials cannot be extrapolated to routine child 
psychiatric care. Hence, more studies of ADHD and mood disorders are needed to 
investigate the effectiveness of medication/psychotherapy in regular treatment. 
In Paper IV, the Pastill data were linked to Swedish national registers to see whether 
CGAS ratings at end-of-treatment predict long-term negative outcomes in young adults. 
To do this, 4,876 patients were followed up prospectively. Patients with CGAS≤60 at 
end-of-treatment had a moderately increased risk of a criminal conviction and a 
substantially increased risk for bipolar disorder and borderline personality disorder during 
follow-up compared to patients with CGAS>60. Low CGAS ratings were not associated 
with depression, suicide attempt, or substance misuse. Hence, CGAS ratings provide 
specific long-term prognostic information, and adolescents with CGAS scores below 60 at 
end-of-treatment should be considered for intensified follow-up. 
SAMMANFATTNING 
Skattningsskalor och diagnostiska instrument har fått en allt större utbredning inom barn- 
och ungdomspsykiatrin de senaste 30 åren. Dessa instrument hjälper behandlare och 
forskare att beskriva psykiatriska diagnoser, symtom och funktionsnivåer på ett mer 
standardiserat och likvärdigt sätt. Denna avhandling beskriver Children’s Global 
Assessment Scale (CGAS), en spridd och användbar skala för att mäta hur barn och 
ungdomar fungerar i vardagen (hemma, i skolan och med kamrater). 
Delarbete I utvärderar reliabiliteten mellan olika bedömare och hur skattningarna 
överensstämmer med expertskattningar. Fem erfarna kliniker skattade fem fallvinjetter för 
att skapa en gold standard. Otränade kliniker (n=703) skattade samma vinjetter och 
resultatet visade att de skattade högre än gold standard. Intra-klass 
korrelationskoefficienten (ICC) var 0,73. Socionomer och psykologer hade en högre risk 
jämfört med läkare för att skatta alla fall tydligt avvikande från gold standard. Resultaten 
visar en måttlig reliabilitet mellan bedömare och en måttlig överensstämmelse i 
jämförelse med experter när otränade kliniker använder CGAS. 
Delarbete II undersöker om två olika utbildningsmetoder, seminarier och CD-skiva, kan 
påverka skattningarnas kvalitet. Otränade kliniker (n=648) lottades mellan de bägge 
träningsmetoderna, och 55 kliniker deltog i den otränade jämförelsegruppen. Det fanns 
ingen skillnad mellan grupperna 12 månader efter träning. Jämförelsegruppen förbättrades 
också i samma storleksordning under uppföljningstiden. ICC vid början och vid 
slutpunkten var 0,71/0,78 (seminarium), 0,76/0,78 (CD), och 0,67/0,79 (jämförelsegrupp). 
Resultaten talar för att använda den datorbaserade träningen i ökad utsträckning, men den 
faktiska förbättringen var liten och inte kliniskt relevant. 
I samband med den omfattande utbildningsaktiviteten ovan påbörjade BUP i Stockholm 
rutinmässiga CGAS-bedömningar som lagras i en klinisk databas, Pastill. Delarbete III 
studerade ”verklighetens” barnpsykiatriska vård utifrån skillnader i psykosocial funktion 
mätt med CGAS. Skillnaden mellan CGAS vid nybesök och avslutad behandling 
undersöktes hos 12,613 patienter. Samtliga diagnosgrupper visade förbättring av CGAS 
efter behandling. Olika typer av psykoterapier visade på samband med förbättring av 
CGAS i depressionsgruppen, men däremot ej farmakologisk behandling. För Attention-
Deficit/Hyperactivity Disorder (ADHD) var inte heller medicinering med 
centralstimulantia associerat med förbättring av CGAS. Resultaten visade sämre utfall i 
jämförelse med kliniska prövningar, framför allt för ADHD, vilket gör att man inte 
självklart kan översätta kliniska studier till verklighetens vård. Både farmakologisk 
behandling och psykoterapi behöver utvärderas ytterligare för ADHD och depression i 
naturalistiska kliniska sammanhang. 
Slutligen länkades Pastilldata till nationella register för att undersöka om CGAS vid 
avslutad behandling kan predicera framtida psykisk sjukdom och kriminalitet hos unga 
vuxna. I delarbete IV följdes 4,876 patienter i 1-1½ år. Ungdomar med CGAS≤60 vid 
avslutad behandling visade en ökad risk för kriminalitet, bipolär sjukdom och borderline 
personlighetsstörning jämfört med gruppen CGAS>60, men däremot ingen riskökning för 
depression, suicidförsök och missbruk. CGAS skattningar vid avslutad behandling kan ge 
information om framtida utfall. Ungdomar med CGAS skattningar som är 60 och lägre 
vid avslutad behandling bör uppmärksammas med tanke på behov av intensifierad 
uppföljning 
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1 PROLOGUE 
Does child psychiatric treatment make a difference? As a young child psychiatrist I 
often wondered if it did, and I was frustrated over the lack of a clear answer. As I 
thought about undertaking Ph.D. research, I realized this question was too 
comprehensive to be addressed in one Ph.D. project. If I wanted to contribute to the 
evidence base for child psychiatry’s effectiveness I needed a more specific research 
question.  
During my residency in child psychiatry I concentrated on learning as much as possible 
about diagnoses, diagnostic criteria, and diagnostic systems. However, at the same time 
I started to find out more about functional impairment, not least due to the growing 
body of knowledge on neuropsychiatric disorders where the level of functioning is the 
key to treatment planning. I realised that although symptom reduction usually precedes 
functional improvement in child psychiatric practise, treatment cannot be considered 
truly successful until the patient also reaches a near-normal or normal functional level. 
This means that the ultimate goal of child psychiatry is to improve children’s 
psychosocial function. Hence, it does not suffice that a depressed adolescent no longer 
meets the diagnostic criteria for depression. He or she should also be able to return to 
school, see friends again and get along at home.  
This line of reasoning led me to the question: how can child psychiatry measure 
psychosocial functioning?  
While I pondered this question, the inpatient unit at Child and Adolescent Mental 
Health Services (CAMHS) in Stockholm decided to start using the Children’s Global 
Assessment Scale (CGAS) in clinical work. This gave me the opportunity to plan a 
training activity and compare the effectiveness of two different training methods. This 
thesis presents the results from these training activities. The CGAS ratings that 
CAMHS in Stockholm began to routinely collect were then used to conduct two large-
scale studies to answer the following questions: i) Is child psychiatric treatment-as-
usual effective in terms of improved psychosocial functioning measured by CGAS, and 
ii) Do CGAS ratings predict future mental health disorders and criminality? 
  2 
2 INTRODUCTION 
2.1 RATING SCALES AND DIAGNOSTIC INSTRUMENTS 
Rating scales and diagnostic instruments are attempts to create objective measures of 
psychiatric symptoms. These tools can consist of a battery of questions, a series of 
statements requiring a yes or no answer, numbered scales corresponding to emotional 
states, functional states, or behavioural patterns, checklists, self-reports, or other 
standardized ways to assess a patient’s symptoms and needs (Myers and Winters 2002; 
Myers and Winters 2002; Ohan et al. 2002; Winters et al. 2002; Collett et al. 2003; 
Collett et al. 2003; Winters et al. 2005). Some tools are clinician-rated, some are self-
rated by the patient, and some are rated by parents or others. 
By allowing for a high degree of standardization, rating scales and diagnostic 
instruments can contribute to many aspects of psychiatry (Shaffer et al. 1999; 
Fitzpatrick et al. 2011). First, standardized instruments provide measureable data that 
help clinicians make evidence-based diagnoses and assess function (Hodges 1993; 
Zanarini et al. 2000; Gilbody et al. 2002; Mazade and Glover 2007; Wolpert et al. 
2007; Garland et al. 2010; Stein et al. 2010; Bickman et al. 2011; Follan et al. 2011). 
Second, these tools are key to obtain replicable data in clinical trials and 
epidemiological surveys (Hoagwood et al. 1995; Hoagwood et al. 1996; Jensen et al. 
1996; Leaf et al. 1996; Fonagy 1997; Myers and Winters 2002; Kim-Cohen et al. 2003; 
Galanter and Patel 2005). Third, health care providers can use rating instruments to 
prioritise health care resources, and to compare different clinical units in quality 
assurance and improvement programmes (Wolpert et al. 2007). A fourth potential 
application is to predict future risk for adverse events, such as mental disorders, 
criminality, substance misuse, accidents, or other factors associated with low quality of 
life. Identifying children at risk for these outcomes might lead to a more prudent use of 
healthcare resources by allowing help to be allocated the most vulnerable. 
Rating scales and diagnostic instruments have become increasingly widespread in 
psychiatric care over the past decades (Myers and Winters 2002), and together with 
evidence-based guidelines they increasingly assist decision-making for clinicians and 
patients (Kendall et al. 2005; Wolpert et al. 2006; National Institute for Health and 
Clinical Excellence 2008; BUP divisionen 2010; Stein et al. 2010; Wolpert et al. 2011). 
This development is in accordance with the fifth edition of the Diagnostic Statistical 
Manual of Mental Disorders (DSM-5) draft, which suggests that assessment and 
diagnosis should be based at least in part on rating scales (American Psychiatric 
Association 2010). 
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2.2 THE DEVELOPMENT OF SCALES 
TO RATE MENTAL HEALTH AND 
FUNCTIONAL IMPAIRMENT 
2.2.1 Historical background 
Prior to 1960, psychiatry used “improvement 
scales” that measured how much a patient had 
improved with treatment, but did not assess the 
patient’s overall level of mental health or 
functioning. Since all patients have different 
baselines, a “much improved” patient could 
have more severe symptoms than a “slightly 
improved” patient. In 1962, the Psychotherapy 
Research Project of The Menninger Foundation 
tried to figure out how clinicians could quantify 
mental health over time in such a way that the 
changes would be comparable between 
patients. The members of the project agreed 
upon seven criteria for judging mental health: 1) the ability to function autonomously, 
2) the seriousness of symptoms, 3) the degree of discomfort, 4) the effect upon the 
environment, 5) the utilization of abilities, 6) the quality of interpersonal relationships, 
and 7) the breadth and depth of interests. The project resulted in a 100-point scale 
where standard patients were graded depending on their degree of overall mental health 
(Luborsky and Bachrach 1974). The score was obtained by comparing the observed 
patient with a series of short vignettes. Launched as the Health-Sickness Rating Scale 
(HSRS), it became one of the first rating scales that included a measure of psychosocial 
functioning in its assessment of mental health (Luborsky 1962). A limitation with the 
HSRS global assessment, however, was that diagnostic terms were included in the 
descriptions. For example, one rating corresponded to “Most clear-cut, overt 
psychoses, psychotic characters, severe addictions (which require hospital care)”. 
Hence, even though the scale included psychosocial functioning, it was essentially 
diagnosis-based, limiting its usefulness for measuring changes in symptoms and 
functioning (Endicott et al. 1976). 
This encouraged Endicott and Spitzer at Columbia University to develop a new rating 
scale that was launched in 1975: the Global Assessment Scale (GAS) (1976). The 
diagnostic terms were removed and examples with behavioural descriptions were 
added. Also, the GAS had a narrower scope than HSRS’s assessment of the overall 
level of mental health, and aimed only to evaluate the overall level of functioning. 
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2.3 THE CHILDREN’S GLOBAL ASSESSMENT SCALE (CGAS) 
In the early 1980s, Shaffer and colleagues - also at Columbia University - used GAS as 
a basis to develop a new scale for use with children and adolescents, 4-16 years old 
(Figure 1) (Shaffer et al. 1983). The scale was coined The Children’s Global 
Assessment Scale (CGAS). CGAS is a clinician-rated tool that aims to assess the 
child’s lowest level of global psychosocial functioning (at home, at school, and with 
peers) during the last month, taking into account all available information. The time 
period may be adjusted depending on the purpose of the ratings. However, it is 
reasonable to let at least one time period pass between repeated ratings to avoid overlap 
of the assessed time period. The scoring ranges from 1 (the most impaired level) to 100 
(superior level of functioning). The scale is divided into 10-point intervals that are 
headed with a description of the level of functioning. The anchor points also contain 
examples of behaviours and life situations adequate for children and adolescents 
matching the level of functioning for each interval.  
CGAS is currently routinely used in many countries to measure psychiatric treatment 
outcomes in spite of the limited amount of research evaluating CGAS in large-scale 
clinical settings. Usually CGAS is administered as one scale among a battery of 
instruments (Gold et al. 2009; National Board of Health and Welfare 2009). In the UK, 
for example, the influential CAMHS Outcome Research Consortium (CORC) chose to 
use CGAS along with the Strengths and Difficulties Questionnaire (SDQ) and the 
Experience of Service Questionnaire (ESQ) as a basis for treatment evaluation 
(Wolpert et al. 2007). 
CGAS has also been used in several longitudinal and epidemiological studies (Bird et 
al. 1993; Milne et al. 1995; Leaf et al. 1996; Steinhausen and Metzke 2001; Canino et 
al. 2004; Petersen et al. 2006; Ayton et al. 2009; Bella et al. 2011). In addition, CGAS 
has been used as one of several outcome measures in both randomised controlled trials 
and observational studies (Table 1). 
  5 
Figure 1. Children’s Global Assessment Scale, original version 1983 (Shaffer et al. 
1983). 
 
 
   
Table 1. Randomised controlled trials and observational studies with CGAS as one of several outcome measures. 
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
ADHD (Berek et al. 
2011) 
Prospective 
non-
interventional 
open-label 
study 
Methylphenidate 
OROS 
n=822, 6-18 y 
12 weeks 
No info/ 
No info 
Treating 
physician 
parent 
interview/ 
No info 
58.5 69.6 11.1 
ADHD (Findling et 
al. 2008) 
Open-label 
pilot trial 
Aripiprazole 
n=36, 8-12 y 
6 weeks 
No info/ 
No info 
No info/ 
No info 
62.8 71.0 8.2 
ADHD (Kratochvil et 
al. 2007) 
Retrospective 
study 
Clinical 
records 
Atomoxetine  
n=22, 5-6 y 
8 weeks 
No info/ 
No info 
3 centers, 
conference 
call/ 
No info 
53.2 Not reported 18.9 
ADHD (Preuss et al. 
2006) 
Prospective 
observational 
study 
ADORE study 
n=1,478, 6-18 y 
2 years 
No info/ 
No info 
MD 10 
European 
countries/ 
No info 
55.2 Only baseline 
data 
 
ADHD (Steinhausen 
et al. 2006) 
Cohort study ADORE study 
Impact of ADHD 
n=1,478, 6-18 y 
2 years 
No info/ 
No info 
MD 10 
European 
countries/ 
No info 
58.5 
55.8 
53.3 
54.8 
57.2 
50.7 
ADHD only 
ADHD + Depr/Anxiety  
ADHD + ODD/CD 
ADHD + Tics/Tourette’s 
ADHD + Coord. probls 
ADHD + ≥2 conditions  
ADHD (Szobot et al. 
2004) 
RCT, double-
blind, placebo-
controlled 
Methylphenidate 
n=36, 8-17y  
4 days 
No info/ 
No info 
CAP MD/ 
No info 
52.1 (MPH) 
54.7 (PLC) 
69.1 - 4 days 
59.7 
17.0 
5.0 
   
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
Anxiety 
disorder 
(McShane et 
al. 2007) 
Uncontrolled 
intervention 
study 
Multimodal 
treatment 
n=24, mean 15 y 
1 year? 
No info/ 
No info 
No info/ 
No info 
58 61 3 
Anxiety 
disorder 
(Monga et al. 
2009) 
Pilot study, 
uncontrolled 
CBT  
n=32, 5-7 y 
12 weeks 
Previous 
month/No 
info 
No info/ 
No info 
46.2 
45.6 
61.2 
55.7 
15.0 
10.1 
Anxiety 
and 
depressive 
symptoms 
(Muratori et 
al. 2002) 
Non-
randomised 
controlled 
study 
Brief dynamic PT 
n=30, 6-11 y 
11 sessions,  
(5 individual) 
No info/ 
No info 
Independent 
blind observer/ 
No info 
61.7 (BDPT) 
 
59.0 (PLC) 
75.3 (6m FU) 
66.3 (18m FU) 
66.3 (6m FU) 
69.7 (18m FU) 
Bipolar 
disorder 
(Barzman et 
al. 2004) 
Uncontrolled, 
retrospective 
chart review  
Aripiprazole 
n=30, 5-19 y 
1-9 months 
No info/ 
No info 
2 CAP MD/ 
No info 
48.0 65.0 17.0 
Bipolar 
disorder, 
mania 
(Pavuluri et 
al. 2005) 
Prospective 
open trial 
Divalproex sodium 
n=34, 5-18 y 
6 months 
No info/ 
No info 
Clinicians 
master level/ 
6 months 
training, IRR 
0.90-0.98 
43.8 56.0 12.2 
Bipolar 
mania, 
Schizo-
phrenia 
 
(Stewart et al. 
2009) 
Open-label 
follow-up 
study 
Ziprasidone, low  
Ziprasidone, high 
dose 
n=63, 10-17 y 
6 months 
One month/ 
Lowest 
level 
No info/ 
Instructions to 
all raters prior 
study 
41.7 (low) 
39.0 (high) 
Reported only 
in diagram 
14.4 (3w) 
17.4 (3w) 
Bipolar 
disorder 
(Tillman and 
Geller 2007) 
Descriptive 
study, 
comparing two 
populations 
RCT group 
Consecutive study 
group 
n=243, 7-15 y 
No info/ 
No info 
Research 
nurses/consens
us conferences 
38.7 
43.7 
  
   
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
Conduct 
disorder 
(Masi et al. 
2006) 
Naturalistic 
follow-up 
study 
Olanzapine 
n=23, 11-17 y 
6-12 months 
No info/  
lowest level 
Experienced 
CAP 
MD/Consensus 
on KSADS 
38.2 50.0 11.8 
Depressive 
disorder 
(Fitzpatrick et 
al. 2011) 
Comparative 
study research 
and clinical 
assessment 
n=100, 12-15 y 
 
No info/ 
No info 
Research 
psychiatrist and 
psychologist/N
o info 
44.9 (depr disorder) 
53.7 (no depr disorder) 
 
Depressive 
disorder 
(Keller et al. 
2001) 
RCT Paroxetine, 
Imipramine, 
Placebo 
n=275, 12-18 y 
8 weeks 
No info/ 
No info 
12 centers/ 
No info 
42.7 (PXT) 
42.5 (IMI) 
42.8 (PLC) 
Not reported  
Depressive 
disorder 
(Mufson et al. 
2004) 
RCT Interpersonal 
Psychotherapy 
Treatment as usual 
n=53, 12-18 y 
12 weeks 
No info/ 
No info 
Psycholo-gist 
or social 
worker, 
blinded/ 
Trained, 21 
clinicians rated 
20 vignettes 
ICC 0.83 
52.6 (IPT) 
52.7 (TAU) 
66.7 (IPT) 
59.5 (TAU) 
14.1 
6.8 
Depressive 
disorder 
(Abeles et al. 
2009) 
Uncontrolled 
intervention 
study 
Computerized CBT 
n=23, 12-16 y 
1-8 sessions  
No info/ 
No info 
No info/ 
No info 
47.0 59.6  
70.1 (12w) 
12.6 
23.1 
Depressive 
disorder 
(Brent et al. 
1997) 
RCT CBT/SBFT/NST 
n=107, 13-18 y 
12-16 weeks  
No info/ 
No info 
No info/ 
No info 
58.8 (CBT) 
54.5 (SBFT) 
56.3 (NST) 
65.4 
63.5 
63.3 
6.6 
9.0 
7.0 
   
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
Depressive 
disorder 
(Emslie et al. 
1997) 
RCT Fluoxetine (FLX) 
n=96, 7-17 y 
8 weeks 
No info/ 
No info 
3 CAP MD/  
Experienced 
47.9 (FLX) 
48.4 (PLC) 
63.9 
60.1 
16.0  
11.7 
ns diff 
Depressive 
disorder 
(Mufson et al. 
1999) 
RCT 
 
Interpersonal 
Psychotherapy/Cont
rol 
n=48, 12-18 y 
12 weeks 
No info/ 
No info 
Independent 
evaluator/ 
No info 
52 No sign 
group diff at 
week 12 
Not 
reported 
Depressive 
disorder + 
IBD 
(Szigethy et 
al. 2007) 
RCT CBT 
Comparison 
treatment 
n=41, 11-17 y 
12-14 weeks 
No info/ 
Current 
level of 
impairment 
Independent 
evaluators, 
psychologists/ 
Training. IRR 
0.90 
61.8 (CBT) 
62.4 (TAU) 
69.9 (CBT) 
62.8 (TAU) 
7.8 
0.9 
Depressive 
disorder 
(Vitiello et al. 
2006) 
RCT Fluoxetine + CBT 
Fluoxetine 
CBT 
Placebo 
n=439, 12-17 y 
12 weeks 
Past week/ 
Level of 
functioning 
Independent 
evaluator, 
blinded/ 
No info 
50.0 (COMB) 
49.5 (FLX) 
50.0 (CBT) 
49.1 (PLC) 
66.6 
62.1 
60.0 
59.3 
16.6 
12.6 
10.0 
10.2 
Depressive 
disorder 
(Wagner et al. 
2003) 
RCT Sertraline  
Placebo 
n=376, 6-17 y 
10 weeks 
No info/ 
No info 
53 units. 
Patient-rated/ 
No info 
50.2 
49.7 (PLC) 
66.0 
64.7 
16.0 
14.7 ns 
Depressive 
disorder 
(Wagner et al. 
2006) 
RCT, double-
blind, placebo-
controlled 
Escitalopram 
Placebo 
n=261, 6-17 y 
8 weeks 
No info/ 
No info 
No info/ 
No info 
52.9 
51.9 
68.5 
64.6 
15.6 
12.7 
   
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
Depressive 
disorder 
Outcomes 
(Wiggins et 
al. 2010) 
Observational 
study 
Treatment as usual 
n=76, 12-18 y 
3 months 
One month/ 
Lowest 
level 
Psychologists, 
social workers, 
nurses, occ 
therapists, 
psychiatrists/N
o info 
52.3 (Depr) 
57.1 (Other) 
62.8 
65.9 
10.5 
(Depr) 
8.8 
(Other) 
Mood 
disorder 
(Cummings 
and Fristad 
2011) 
Randomised 
clinical trial 
MF-PEP 
Waiting list (Ctrl) 
n=165, 8-11 y 
18 months follow-
up 
No info/ 
No info 
2 psycholo-
gists reviewed 
reports, 
consensus/ No 
info 
43.0 
44.4 
More baseline 
anxiety 
symptoms 
assoc w 
greater CGAS 
improvement 
 
OCD (Rosenberg et 
al. 1999) 
Uncontrolled 
intervention 
study 
Paroxetine 
n=20, 8-17 y 
12 weeks 
No info/ 
No info 
Treating MD, 
review by CAP 
MD?/ 
No info 
46.8 57.5 10.7 
OCD (Valderhaug 
and Ivarsson 
2005) 
Observational 
study, Norway 
and Sweden 
n=68, 8-17 y 
 
No info/ 
No info 
CAP MD, 
psychologist or 
nurse/ 
No info 
49.6 Swe 
55.6 Nor 
  
Outcomes (Garralda et 
al. 2000) 
Naturalistic 
follow-up 
study 
Treatment as usual 
(TAU) 
6 months  
n=248, 3-18 y  
(n=191, 4-16 y 
CGAS) 
One month/ 
Level of 
functioning 
31 clinicians,  
7 disciplines/ 
30-60 min 
training of 
HoNOSCA 
53.9 60.9 7.0 
   
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
Outcomes (Gold et al. 
2009) 
Naturalistic 
follow-up 
study 
Inpatient n=398 
Acute residential 
n=350 
Partial hospital 
n=203 
Outpatient n=202 
Mean age 13.4 
90 days/discharge 
One month/ 
Lowest 
level 
Clinicians 20 
sites/ 
No info 
32.8 (Inpat) 
44.1 (AR) 
45.7 (PH) 
55.7 (Outpat) 
47.8 
49.8 
51.6 
58.8 
15.0 
5.7 
5.9 
3.1 
Outcomes (Setoya et al. 
2011) 
Prospective 
study 
Inpatient treatment 
as usual 
n=126, <15 y 
11 months (mean) 
One month/ 
Lowest 
level 
Attending 
psychiatrist/ 
No info 
38.1 57.9 19.8 
Psychosis (Castro-
Fornieles et 
al. 2011) 
Non-
interventional 
follow-up 
Pat with psychotic 
symptoms 
n=83, 9-17 y 
2 years follow-up, 
stability of 
diagnosis 
No info/ 
No info 
Research 
psychiatrists 
psychologist/ 
Training 
33.2 (mean) 
22.9  
32.7  
50.0  
31.7 
65.8 (mean) 
Schizophrenia at endpoint 
No schizophrenia at endp. 
No diagnosis at endpoint 
Any disorder at endpoint 
Schizo-
phrenia 
(David et al. 
2011) 
Descriptive 
study 
Document non-
auditory 
hallucinations 
n=117, 6-17 y 
No info/ 
No info 
No info/ 
No info 
38.7 admission / No visual hallucination 
33.1 drug-free / No visual hallucination 
31.8 admission / Visual hallucinations 
22.7 drug-free / Visual hallucinations 
Schizo-
phrenia 
(Findling et 
al. 2003) 
Prospective 
open-label trial 
Olanzapine 
n=16, 12-17 y 
8 weeks 
No info/ 
No info 
No info/ 
No info 
41.9 52.7 10.8 
   
Diagnosis/ 
Theme 
Author Study design Intervention 
Number, Age 
Duration 
C G A S 
Time period/ 
Level 
Rater 
background/ 
Training 
Baseline Endpoint ∆CGAS 
Schizo-
phrenia 
(Sporn et al. 
2007) 
Long-term 
follow-up 
study 
Clozapine 
n=54, 7-19 y  
n=33  
5 y follow-up 
No info/ 
No info 
No info/ 
No info 
24.1 40.2 after 6 w 
41.5 after 2-5 y 
16.1 
Self-harm, 
suicidal 
and non-
suicidal 
(Ougrin et al. 
2011) 
RCT 
 
Therapeutic 
assessment 
AAU  
n=70, 12-18 y 
3 month follow-up 
No info/ 
No info 
3 higher spec 
trainees in 
psychiatry/ 
No info 
53.3 
suicidal 
54.8 non-
suicidal 
Nonsuicidal 
higher CGAS 
after 3 months 
than suicidal 
 
Tourette (Gorman et 
al. 2010) 
Descriptive 
study 
n=65, 18 y Tourette 
n=65, 18 y Controls 
No info/ 
No info 
2 CAP MD, 
consensus 
procedure/ 
No info 
56.4 (T) 
70.4 (C) 
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2.3.1 Swedish translation 
P. Gustafsson & M. Helgesson translated CGAS into Swedish in 2001. In 2005, a 
translator and I revised the translation, which was then back-translated from Swedish 
into English. This work was done in collaboration with the research group at Columbia 
University that developed CGAS. The age span was increased from 4-16 years to 4-20 
years. The revisions and change of the age span were discussed and approved of by the 
research group at Columbia University. CGAS has since been used in numerous 
Swedish research and clinical settings (Figure 2) (National Board of Health and 
Welfare 2009). 
2.3.2 Reliability 
Prior to the launch of CGAS, Shaffer and his colleagues tested the scale’s inter-rater 
reliability and stability. In order to minimize variation due to clinical background, a 
group of five medical residents participated as raters (Shaffer et al. 1983). The 
intraclass correlation coefficient (ICC) was 0.84, which lies in an interval considered to 
correspond to “substantial” inter-rater reliability according to Shrout (1998). All but 
one rater were consistent over time when rating the vignettes after 6 months, yielding 
an ICC of 0.85. 
A few years later Steinhausen evaluated the properties of the scale both in a research 
setting with vignettes (14 raters) and in a clinical setting (number of raters not 
accounted for) (1987). The inter-rater reliability, expressed as ICC, was 0.93. 
Interestingly, the stability coefficient (the intra-rater reliability, measuring agreement at 
two different time points for the same rater) varied between 0.22 and 0.85 and showed 
less agreement in cases with less severe emotional disorders than in cases with severe 
or more clear-cut single symptom disorders. The diagnostic agreement was also lower 
between the clinicians when assessing patients with less severe emotional disorders.  
The ICC in other clinical settings ranges from 0.53 to 0.90, with the number of raters 
spanning from 2 to 20 (Rey et al. 1995; Dyrborg et al. 2000). Importantly, however, the 
results from these reliability studies  comprising few raters with homogeneous 
background cannot be generalized to nationwide clinical settings involving large groups 
of heterogeneous raters. A recent study investigated the inter-rater reliability of CGAS 
in a somewhat larger clinical setting (n=78) (Hanssen-Bauer et al. 2007). All 
participants received general information about CGAS followed by a discussion on 
how to rate five short written vignettes before rating the written case vignettes. The 
inter-rater reliability was fair to moderate as indicated by an ICC of 0.61 (Shrout 1998), 
considerably lower than the ICC of 0.84 in Shaffer’s original study (Shaffer et al. 
1983). 
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Figure 2. Children’s Global Assessment Scale, Swedish version 2005. 
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2.3.3 Validity 
To validate CGAS, one needs a reference CGAS score or similar measures against 
which ratings can be compared. The most commonly used approach to define a “true” 
CGAS rating is to analyse the post hoc mean rating of a group of raters. An alternative 
approach is to use experienced clinicians to reach a best estimate that is then defined as 
a “gold standard” (Wu et al. 2007). The latter method has been employed in a study 
involving a total of 30 raters from 5 countries (but only 15 of them did the CGAS 
ratings, 3 from each country), where each national group made a consensus rating of 
case vignettes (Hanssen-Bauer et al. 2007). The expert rating made by consensus was 2 
points lower than the mean rating of the 15 participants. This difference was not 
considered clinically relevant.  
Each method of establishing a “true” CGAS value for a patient has advantages and 
disadvantages. Using the mean group rating as a reference is straightforward and easy. 
However, this method does not control for the raters’ professional training, clinical 
experience, familiarity with rating tools and diagnostic instruments, or attitudes towards 
such instruments, all of which are likely to affect their ratings (Söderberg et al. 2005). 
Using expert raters is more complicated and resource demanding. The advantage of 
using experienced clinicians, however, is that these expert raters have sufficient training 
in child psychiatry, broad experience with rating instruments, and generally a positive 
attitude towards them, all of which are likely to make their ratings more valid. In my 
opinion, this speaks in favour of using expert raters. This strategy is also in accordance 
with the way in which a gold standard is established in diagnostic assessments, where 
experienced clinicians rely on semi-structured instruments as well as the opinions of 
other experienced clinicians. 
As to external validity, research has found that CGAS ratings correlate fairly well with 
a child’s intellectual functioning, school competence as rated by parents, and social 
skills as rated by clinical staff in clinical settings (Weissman et al. 1990; Green et al. 
1994). Furthermore, CGAS ratings have been found to agree with ratings from the total 
Behaviour Problem Score and the Social Adaptation Score of the Child Behaviour 
Check List (CBCL) in epidemiological settings (Bird et al. 1987). Moreover, 
discriminant validity has been established in a study that found significantly lower 
CGAS scores in a group of children referred to mental health services than in a group 
of children that was not referred, and in which a group of clinical “cases” scored lower 
on CGAS than did “non-cases” (Bird et al. 1987). 
2.3.4 CGAS, a forerunner to the Global Assessment of Functioning (GAF) 
The Global Assessment of Functioning (GAF) is a rating scale similar to CGAS. GAF 
is a widespread tool in adult psychiatry and in some child and adolescent psychiatric 
settings. A common misconception is that CGAS is a children’s version of GAF, but 
GAF is in fact a hybrid of GAS and CGAS that was developed in conjunction with the 
DSM-III-R (American Psychiatric Association 1987).  
GAF was designed for use with both children and adults. There are particular 
advantages to using a scale appropriate for all ages, especially in longitudinal studies. 
The disadvantage, however, is that the descriptions of different levels of functioning 
must be general enough to fit the whole life span, which may degrade face validity and 
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hamper specificity. For child and adolescent use, it is therefore an advantage that the 
CGAS descriptions are adapted specifically for children and adolescents. 
In the original introduction of CGAS (Shaffer et al. 1983) it is clear that the scale 
should be used to assess the most impaired level of psychosocial functioning during the 
last month. (There are, however, many examples of studies in which these instructions 
are not followed, as elaborated below in the General Discussion.) The GAF 
assessment, by contrast, reflects the lowest level of either symptom severity, level of 
functioning or a combination during a time period defined by the clinician (American 
Psychiatric Association. 2000). These loose instructions for GAF users inevitably lead 
to a diverse array of rating strategies (highest, lowest and average) and hamper 
comparisons of GAF ratings between study populations (Bates et al. 2002). A final 
difference between CGAS and GAF is that the range that is defined as serious 
impairment of psychosocial functioning differs between the two scales (CGAS 1 to 40, 
GAF 1 to 50). 
2.3.5 Global functioning and DSM 
Ever since the DSM-III was published in 1980, the definition of mental disorders has 
included both symptomatic criteria and functional impairment (American Psychiatric 
Association 1980; 1987; 1994; 2000). However, in clinical practice diagnostic criteria 
are not primarily used to decide if a child needs treatment; defining clinical caseness is 
instead an issue of clinical judgement. This is a problem in research where the 
definition of caseness needs to be operationalized. Several studies have shown that the 
number of cases - expressed as the overall prevalence of a psychiatric disorder - is 
markedly reduced when a functional impairment rating with CGAS is added to the 
diagnostic procedure. This is true whether using DSM-III-R (American Psychiatric 
Association 1987; Bird et al. 1993) or DSM-IV-TR (American Psychiatric Association 
2000; Canino et al. 2004). This suggests that combining diagnostic criteria with a 
measure of psychosocial functioning may be the best way to classify a disorder. 
2.4 CLINICAL EDUCATION IN THE USE OF RATINGS SCALES AND 
GUIDELINES  
It cannot be assumed that the studies summarised above, that investigate CGAS 
reliability and validity in small groups of clinicians, can be extrapolated to naturalistic 
circumstances that involve large heterogeneous groups of raters. Before using CGAS in 
large clinical settings, we therefore need to find out whether practitioners use CGAS 
consistently enough to make it a useful tool in evidence-based child psychiatry. This 
information on the quality of the ratings is important to professionals, researchers, and 
managers relying on CGAS for their work.  
Paper I in this thesis examined the inter-rater reliability when a large group of untrained 
practitioners used CGAS.  
2.4.1 GAF and CGAS rater training 
When CGAS was introduced in 1983, there were no instructions as to whether training 
was required prior to employing the tool in research or clinical settings (Shaffer et al. 
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1983). At Columbia University, however, it has been common practice to introduce 
CGAS by gathering researchers/clinicians to discuss some cases together to ensure that 
everyone rates cases within the desired range of ±5 points (personal communication 
Prudence Fisher). Several researchers, however, have suggested that the lack of 
standardized and evaluated training material may jeopardize the quality of ratings 
(Schorre and Vandvik 2004; Winters et al. 2005; Rush et al. 2008), and numerous 
researchers whose studies are based on the similar GAF scale have suggested that users 
should undergo training before using GAF (Fernando et al. 1986; Goldman et al. 1992; 
Hilsenroth et al. 2000). There are, however, no studies to date on the actual effects of 
training on the reliability and validity of CGAS ratings. In one of the few studies that 
looked at training’s effect on the use of GAF, brief one-hour training sessions improved 
participants’ understanding of how to use the scale, but did not bring ratings closer to 
the expert rating enough to be clinically relevant (n=31) (Bates et al. 2002). 
Even though there are no studies evaluating the effect of CGAS training, there are 
studies that have performed training prior to the use of the scale. In one small-scale 
study, five raters read the available literature about CGAS and the Global Assessment 
of Psychosocial Disability scale (GAPD) for two months before the study was initiated 
(Dyrborg et al. 2000). Three of the raters in the study, all experienced clinicians, also 
met weekly and agreed upon some ratings each time. The results showed that the 
agreement between raters was higher among those who were clinically experienced and 
had performed more than 50 CGAS ratings. This observation indicates that practice can 
improve the quality of ratings. In another recent study, there was no positive effect on 
inter-rater reliability from feedback given to a group of raters about 1) how they rated 
vignettes themselves and 2) how three experienced clinicians had rated vignettes 6 
months before they received new vignettes (Hanssen-Bauer et al. 2007). 
2.4.2 Designing and evaluating successful training 
The lack of evaluated training programmes for rating scales like CGAS raises questions 
about to how a training model can be constructed so that it can be used by large groups 
of practitioners. Training methods that only include dissemination of information to 
passive participants have not been shown to have an impact on professional skills 
(Davis et al. 1995; Bero et al. 1998). This finding has lead to an increased focus on 
active learning in medical universities (Biggs 2003).  
There has also been little discussion about how “improvement” in CGAS rating skills 
should be defined and how the effect of training should be evaluated. A possible 
explanation is that the original work presupposed that clinicians could use the scale 
without training. Kirkpatrick & Kirkpatrick provides a Four Level Model to evaluate 
training programmes generally in corporate, government, and academic worlds (2005). 
The first level, reaction, is evaluated in most training settings. This can be done with 
“happy sheets” or surveys collecting information about the participants’ experiences 
from the training. Even though the reaction level says nothing about what the 
participants learned, a positive reaction promotes successful learning (Kirkpatrick and 
Kirkpatrick 2005). Learning is the second level evaluated and consists of assessments 
of knowledge increase, skills improvement, and changed attitudes. The second level 
can be fulfilled without discernible behavioural changes, which are evaluated at level 
three. The last and fourth level, results, evaluates changes that take place in a whole 
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organization as a result of training, for example, if clinicians were to more regularly 
assess the level of psychosocial functioning with CGAS and use the information in 
treatment planning. 
2.4.3 Computer-based training 
Gathering all clinicians for scheduled seminars consisting of both skills practice 
training and basic theoretical background education would be time-consuming and 
costly in large organisations. New employees arrive, some people work part-time, and 
some are out of work due to sickness or parental leave. A computer-based method with 
interactive training available through a Compact Disc (CD-ROM) or the Internet would 
be a more flexible way to offer CGAS training, as it is available whenever clinicians 
have time. It could also be a cost-efficient way to train raters in large clinical settings. 
The use of such methods has, however, not previously been evaluated.  
Paper II in this thesis evaluates two types of training methods, a seminar and a 
computer-based training module, with respect to their effect on rating improvements as 
defined by agreement with expert raters. Both training methods combined theoretical 
background information about CGAS with practical training in its use, and were 
thereby more extensive than any previously described training or introduction to CGAS 
or GAF (Bates et al. 2002; Hanssen-Bauer et al. 2007). 
2.5 EFFICACY VERSUS EFFECTIVENESS 
Clinical guidelines within CAMHS are based mainly on Randomised Controlled Trials 
(RCTs), since these efficacy trials are the gold standard for evidence-based medicine 
(Weisz et al. 1995; Fonagy 1997; Gilbody et al. 2002). Such trials differ, however, 
from routine care in many respects, which limits the generalisability of their findings. 
First, clinical efficacy trials typically enrol patients with a clear-cut diagnosis without 
co-morbidity in order to produce a homogenous patient group. Exclusion criteria 
typically prevent enrolment of children/adolescents (and/or parents) with alcohol or 
drug abuse, reported physical abuse, mental retardation, pervasive developmental 
disorders, major neurological or medical illness, eating disorders, psychosis, bipolar 
disorder, significant suicidal ideation, long periods of absence from school, and other 
co-morbid axis I or II conditions. Applying these exclusion criteria effectively excludes 
large numbers of patients who actually receive treatment within CAMHS (Fonagy 
1997; Bridge et al. 2009). Second, research has shown that not only patients’ but also 
clinicians’ behaviour differ between a research setting and a naturalistic setting 
(Kendall and Southam-Gerow 1995). Third, high expectations are more common in 
research patients and have shown to correlate with better outcomes (Lambert et al. 
2004, p. 205). Lastly, it is likely that treatment compliance is better in clinical trials 
than in naturalistic settings. 
Because of these limitations with RCTs’ applicability to real world psychiatric settings, 
clinical efficacy trials need to be complemented with effectiveness studies that take 
place in real world settings with unselected heterogeneous groups of both patients and 
clinicians (Weisz et al. 1995; Weisz et al. 1995; Gilbody et al. 2002; March et al. 2004; 
Mufson et al. 2004). Unfortunately, such effectiveness studies are scarce compared to 
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RCTs evaluating efficacy (Hoagwood et al. 1995; Weisz et al. 1995; Weisz et al. 1995; 
Jensen et al. 1996; Garland et al. 2010).  
An important source of information when conducting effectiveness research is 
routinely collected clinical data. This is also the basis of outcomes research, the field of 
research that studies the ultimate effect of medical care on the health and well-being of 
patients and populations. The results from outcomes research are used to compare 
existing treatments, improve the quality of care, and evaluate new treatments without 
the expense of clinical trials and the loss of generalisability (Ellwood 1988; Busch and 
Sederer 2000; Gilbody et al. 2002). Outcomes research can also investigate cost-
effectiveness under routine conditions.  
The management of CAMHS in Stockholm has long endorsed the importance of 
outcomes research, and the clinical database Pastill – described in detail under Methods 
– is an effort to facilitate such work. Soon after the training activity evaluated in Paper 
II, CGAS ratings were being registered in Pastill from 1 July 2006. Adding CGAS 
ratings to the database Pastill made it possible to design an effectiveness study, in 
which change in CGAS ratings served as the outcome measure of child psychiatric 
treatment. This work is described in Paper III.  
2.6 THE IMPORTANCE OF PROGNOSTIC TOOLS 
Longitudinal studies have shown an increased rate of negative adulthood outcomes in 
child psychiatric populations compared to healthy children (Engqvist and Rydelius 
2006; Engqvist and Rydelius 2007; Mordre et al. 2011). However, there is a 
considerable spread of risk for long-term adverse outcomes also within the child 
psychiatric population, and longitudinal studies following children with mental 
disorders into adulthood have revealed various patterns of developmental trajectories 
with respect to diagnoses, behaviours, and functional outcomes (Colman and Jones 
2004; Thompson et al. 2010). If patients who are at higher risk for psychiatric 
disorders, substance misuse, or criminality could be identified early, intervention 
programs could be targeted to those who need it the most. This would facilitate a more 
prudent use of healthcare resources and ultimately increase psychiatric services’ ability 
to prevent suffering (Leaf et al. 1996; Steinhausen and Metzke 2001; Canino et al. 
2004; Sourander et al. 2004). To this end, clinicians need more knowledge about how 
mental disorders develop as well as valid tools for risk assessment. 
Most longitudinal studies of adverse outcomes in child psychiatric patients are based on 
the association with categorical childhood psychiatric diagnoses rather than 
psychosocial functioning (Rutter et al. 1976; Kim-Cohen et al. 2003; Engqvist and 
Rydelius 2007; Sourander et al. 2007; Pickles et al. 2010; Mordre et al. 2011). For 
example, the risk of recurrent depression in adulthood has shown to be higher among 
those who suffer from depression during adolescence (Lewinsohn et al. 2000). 
According to another study, depressed adolescents also report more impaired familial 
and social relationships, and negative effects on work and school performance than 
normal controls (Geller et al. 2001). Furthermore, childhood conduct problems with or 
without attention-deficit hyperactivity disorder (ADHD) have repeatedly been 
associated with future criminality (Fergusson et al. 2005; Olsson et al. 2006; Engqvist 
and Rydelius 2007; Satterfield et al. 2007; Sourander et al. 2007; Forsman et al. 2010; 
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Mordre et al. 2011). Conduct disorder and oppositional defiant disorder have also been 
associated with psychiatric disorders later in life (Rutter et al. 1976; Kim-Cohen et al. 
2003; Fergusson et al. 2005), especially in girls (Olsson et al. 2006).  
However, using categorical diagnoses as prognostic tools has several limitations. For 
one, psychiatric diagnoses in younger children have been shown to have a low 
predictive value (Bennett and Offord 2001; Kim-Cohen et al. 2003; Kendler et al. 
2008), partly due to the high rate of comorbidity (Bird et al. 1993; Angold et al. 1999). 
Also, a categorical diagnosis does not inform us about the severity or consequences of a 
disorder (Bird et al. 1990; Canino et al. 2004), which is information that presumably 
adds prognostic information. One way to improve prognostic precision might therefore 
be to combine diagnostic information with ratings of psychosocial functioning, for 
example CGAS ratings. However, it is as yet unknown if CGAS predicts future 
negative outcomes in young adults. In the only study to date on the subject, 
retrospective CGAS ratings at intake based on hospital records did not differ between 
later convicted and non-convicted adults in a 30 years follow-up study of 541 child 
psychiatric inpatients (Mordre et al. 2011). If CGAS ratings could be shown to contain 
prognostic information, they could help clinicians identify early those individuals who 
are at risk for psychiatric disorders, substance misuse, or criminality. 
The large number of registered patients with CGAS ratings in the clinical database 
Pastill enabled a prospective follow-up study to examine the predictive properties of 
CGAS. In Paper IV, CGAS scores were linked to national registers and the risk of 
negative outcomes was analysed. 
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3 AIMS 
Despite the widespread use of CGAS to assess global functioning, little is known about 
the accuracy of the instrument in routine clinical care, and whether training 
programmes to improve precision are worthwhile. Moreover, there is a dearth of 
studies assessing the effectiveness of child and adolescent psychiatry treatment by 
means of psychosocial functioning. Finally, the use of CGAS for long-term treatment 
planning is limited because the prognostic value of the scale is unknown.  
 
Against this background, the specific aims of this thesis were to: 
1. investigate the inter-rater reliability and the accuracy in terms of agreement 
with expert ratings when CGAS is used in a large-scale naturalistic clinical 
setting.  
2. compare the effectiveness of two different training methods, live seminars and 
computer-based training, and to estimate the overall effect of training to 
improve CGAS ratings.  
3. investigate the effectiveness of child psychiatric outpatient treatment as 
measured by change in CGAS ratings, and to identify predictive factors for 
CGAS change. 
4. investigate whether CGAS ratings can predict future mental health disorders, 
suicide attempts, criminal conviction, substance misuse, and accidents. 
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4 METHODS 
Herein, the methods used in each study are briefly presented. The full account of the 
methods used are given in the respective paper.  
4.1 PAPERS I AND II  
The first two studies in this thesis evaluated inter-rater reliability and the accuracy of 
CGAS ratings among untrained raters in a large clinical setting. Different methods to 
improve CGAS ratings were also evaluated. I capitalized on the fact that the 
implementation of CGAS in Stockholm CAMHS was accompanied by a training 
activity for which I was responsible. Baseline data were collected between October 
2005 and June 2006, and end-of-study data between October 2006 and June 2007.  
4.1.1 Introduction of CGAS in Stockholm 
In 2000, Stockholm County Council decided to implement the use of GAF for 
assessment of all psychiatric patients, including children and adolescents. GAF patient 
ratings were to be recorded and followed over time as part of a quality improvement 
programme throughout the county (which comprises the greater Stockholm region). 
In 2006, all CAMHS in Stockholm switched to using CGAS instead of GAF. The 
ratings were registered in the clinical database Pastill (described below, Paper III and 
IV). It has been difficult to find any documentation of discussions between health 
administrators and management at CAMHS regarding the decision to change scales, 
and to understand how the ratings were intended to be used. 
In 2008, the Stockholm County Council launched a remunerative incentive scheme to 
increase the use of CGAS (Personal communication, Yvonne Björklund, Department of 
Finance, CAMHS 2011). Health administrators decided that 3% of the total budget 
(590 million SEK) for CAMHS in Stockholm County Council would be available only 
if  
1. >85% of patients with three visits or more had CGAS ratings at intake and at 
end-of-treatment 
2. >90% of patients had an ICD-10 or DSM-IV-TR diagnosis 
3. >90% of patients had an individual treatment plan  
There were no quality requirements in terms of reliability measures (for example inter-
rater reliability and accuracy in ratings compared to expert ratings) or formal training 
coupled to the reimbursement programme. There was no explanation of how the 
collected ratings would be used. Previous research has found that the quality of GAF 
ratings is related to the raters’ attitude towards the scale (Söderberg et al. 2005), 
suggesting that introducing mandatory use of CGAS in this way may not have been 
optimal. I was asked to be responsible for training clinicians throughout the county in 
the use of CGAS. 
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4.1.2 Raters and units 
A total of 703 health care professionals participated in Papers I (Lundh et al. 2010) and 
II (Lundh et al. 2011), of which a majority (n=624) were from CAMHS in Stockholm 
County. CAMHS health care professionals in the counties of Östergötland (n=24), 
Norrbotten (n=21) and Småland (n=34) also participated.  
A total of 33 CAMHS (29 outpatient units, 4 inpatient units) were represented, of 
which 25 outpatient and all 4 inpatient units were located in Stockholm County.  
A total of 648 raters comprised the intervention groups, and 55 raters were included to 
form a non-randomised comparison group.  
There were approximately 770 CAMHS employees in Stockholm during the years the 
study was conducted (Personal communication, Maria Norrbin, Human Resources 
CAMHS 2011). Hence, more than 80% (624/770) of the health care professionals in 
Stockholm participated in the study. 
Demography and background characteristics of the raters were recorded anonymously 
on coded forms. The raters were psychologists, social workers, medical doctors and 
other staff members (nurses, psychiatric technicians, special education teachers, 
occupational therapists etcetera). The vast majority had no experience using CGAS, but 
a majority had used GAF. 
4.1.3 Development of written case vignettes and expert ratings 
The vignettes used in the study were based on actual patients’ first visits at CAMHS in 
order to provide a more realistic and richer presentation than the cases on a website 
providing training vignettes (WIMHRT 2009). Changes were made in the histories in 
order to make it impossible to trace the case vignette to a specific patient, clinician or 
unit.  
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Four experienced clinicians were asked to participate as expert raters together with me. 
This number was chosen to create a group that could reach a consensus on 50 cases 
during 1 day. The group consisted of three child and adolescent psychiatrists and two 
psychologists, with a mean experience in child and adolescent psychiatry of 12 (range 
6-20) years. They all had expertise and skills in the use of structured psychiatric 
interviews and rating scales. They also had a positive attitude towards using different 
tools in their clinical work. These five experts first rated the cases individually. 
Thereafter, a joint discussion resulted in a consensus rating for each case, henceforth 
referred to as the “expert rating” or “gold standard”.  
A sample of ten vignettes was selected by me to provide cases that varied in age, sex, 
level of functioning, and problem area. Only five vignettes were used for baseline and 
end-of-study ratings to ensure that all raters would have time to finish the ratings within 
the one-hour that was at our disposal. The other five vignettes were used in the training 
activity. 
4.1.4 Rating procedures 
The flow chart below (Figure 3) displays the time schedule and the number of 
participants for each step in the rating procedure. 
All participants rated the same five written vignettes individually at baseline. Raters 
were randomised to receive training with either a seminar or an interactive CD-ROM. 
Every CAMHS unit head was instructed to randomise the participants in advance.  
After completion of the baseline ratings, the raters in the computer-based intervention 
group were given a CD-ROM with instructions to complete the training during the 
following week. Those who were randomised to the seminar group continued with their 
training after a break. Within a week after the training, participants completed a 
questionnaire via the Internet assessing their satisfaction with the training. 
The follow-up rating was scheduled to occur after 6 months, but due to the great 
interest in the training programme, the follow-up had to be postponed to make room for 
additional training sessions in the county. During the 10-12 month follow-up period, all 
raters in the intervention groups were requested by the CAMHS administration to do 
clinical CGAS ratings in their daily practice. At the follow-up, the five baseline 
vignettes were rated again.  
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Figure 3. Flow chart Papers I and II. 
 
4.1.5 Training programmes 
The training programmes were developed based on knowledge about clinical training 
methods (Davis et al. 1995; Bero et al. 1998), combining a theoretical and a practical 
part. The seminar group also engaged in a discussion. It should be pointed out that the 
training method employed in this thesis is a more thorough procedure than prior, non-
evaluated, training activities of CGAS (Dyrborg et al. 2000; Hanssen-Bauer et al. 2007) 
Each seminar lasted about two hours and I conducted all of them (31 seminars in total). 
The seminars were highly structured in order to be as similar as possible. The 
theoretical part consisted of information on the history of CGAS, its psychometric 
properties, and rating techniques. The raters were instructed to identify the CGAS score 
that best matched the lowest level of global functioning during the last month. Skills 
training followed the theoretical part of the seminar in groups of two or three. Five 
training vignettes were rated, one at a time. The small groups reported their scores on a 
whiteboard that was viewed by the whole group and thereafter I led a discussion. At the 
end the “expert rating” was revealed, followed by a short explanation of how they 
motivated that rating. 
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The computer-based training 
covered the same topics as the 
seminar. After reading the 
vignette on the screen, the rater 
identified a score on the CGAS 
scale that was then entered into 
the computer. The rating was 
compared with the expert 
rating. If the rating was more 
than ±5 points but less than ±25 
points off from the expert 
rating, the rater received a 
comment that the rating was too 
low or too high and was asked 
to try again. If the rating was 
more than ±25 points off from 
the expert rating, the rater 
received a comment included that his or her rating was not reasonable. The rater was 
encouraged to reread the case and perform a new rating. 
4.1.6 Definition of aberrant rating  
Ratings five points higher or lower than the expert values were defined as aberrant 
ratings for the purposes of this study. This range of ±5 points was decided based on the 
fact that the common range of CGAS improvement in clinical trials is from five to 
fifteen points (see Table 1), and based on informal guidelines from Columbia which 
consider ten points around a mean rating to be desirable and acceptable. In Paper I, 
when a participant rated all five cases outside the range of ±5 points, this was defined 
as an overall aberrant rating. The raters could hence be divided into two groups: 
overall aberrant raters and not overall aberrant raters. The latter category included 
those who were aberrant raters on some but not all cases, as well as the single 
participant with no aberrant ratings at all. The risk of aberrant ratings was analysed in 
Paper I for different groups i.e. age, sex and professional background. 
4.1.7 Statistical methods 
The ICC was used to determine the inter-rater reliability (Bland and Altman 1996). The 
analysis of overall aberrant raters was conducted using a logistic regression model to 
explore which factors could discriminate between overall and not overall aberrant 
raters. All tests were two-sided and p<0.05 was regarded as a statistically significant 
result. In Paper II, results are presented as complete cases analyses, i.e., only subjects 
who had eligible observations at both baseline and end-of-study were included in the 
analysis.  
4.2 PAPERS III AND IV  
CGAS ratings and other clinical data from the database Pastill (described below) were 
used in Papers III and IV. The registration of CGAS in Pastill offered a unique 
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possibility to use a large number of routinely collected CGAS ratings by a group of 
trained raters from real world child psychiatry.  
4.2.1 Setting 
In Papers III and IV, all subjects were patients within CAMHS in Stockholm County. 
This service consists of both inpatient and outpatient clinics and provides mental 
healthcare in a catchment area comprising 420,000 children and adolescents (age 0-17 
years). There are 14 regular outpatient clinics and four clinics working with intensive, 
often home-based, outpatient treatment. Seven outpatient clinics provide specialized 
care either for particular diagnostic groups or employ specific treatment models.  
4.2.2 The clinical database Pastill 
During the 1990s, CAMHS sought to develop and expand the collection of data on 
patients that began in the 1950s, for use in quality assurance programs and in future 
research. No specific research questions, however, guided what variables should be 
collect, a well-known phenomenon in outcomes research (Gilbody et al. 2002). The 
clinical database Pastill was launched in 1998. After one year, all outpatient clinics 
were equipped with computers and data were registered online. In 2003, the inpatient 
clinic joined the project. Between 2001 and 2010, 165,000 cases were registered, 
representing 109,000 unique children and adolescents. Since the inception of Pastill, 
variables have been added and changed to meet needs and interests of clinicians, 
administrators, and managers. Today, epidemiological researchers meet regularly with 
representatives from CAMHS to discuss how to improve future data collection and how 
data can be used for research. 
To enter data into Pastill, the clinician managing the case either fills in a paper form or 
registers the required information online. The information needed for the registration is 
collected both during the intake interview of the patient and family (and school if 
possible), and at the end of the treatment period. Table 2 presents some of the many 
variables recorded in Pastill.  
 
Table 2. Variables in the clinical database Pastill.  
Age at intake 
Status as asylum seeker 
Cause of referral 
Global Assessment of Functioning (GAF) (until 30 June 2006) 
Children’s Global Assessment Scale (CGAS) (from 1 July 2006) 
Clinical assessment report  
Clinical issues/ problems addressed  
Nationality 
Diagnosis according to the DSM-IV-TR and/or ICD10 
Family situation, special circumstances, i.e., death of a parent or a sibling, adoption, 
sibling with severe medical illness  
Family situation, who the child lives with 
Given treatment 
Initiator of the contact with CAMHS / Referral source 
Legal guardian 
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Provided care levels  
Medication other than central stimulants 
Medication with central stimulants  
Neighbourhood  
Interventions aiming at patient’s social network, collaboration with other caregivers  
Number of appointments/telephone calls 
Overall assessment of treatment outcome, according to clinician 
Overall assessment of treatment outcome, according to family/adolescent 
Parent visitation 
Prior contact with CAMHS and at what age 
Psychosocial stressors 
Sex 
Siblings 
Strengths and Difficulties Questionnaire (SDQ) 
The Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) 
Time period from contact to first appointment 
Time period from contact to first offered appointment 
Treatment performed outside CAMHS 
Established treatment plan  
Type of daily activities i.e. day care, school, work 
Variables possible to add, general or local for different units 
 
Out of 29 diagnostic alternatives available in Pastill, 26 adhere to the headings in DSM-
IV-TR and/or ICD 10. The other three alternatives include “lack enough information to 
perform a diagnostic assessment”, “diagnostic criteria not fulfilled”, or “other”. It is 
possible to choose more than one diagnosis. Diagnostic categories are listed in Table 8. 
The variable describing treatment given has evolved since the first version of Pastill 
due to changes in treatment options available within CAMHS. Treatment options 
available for Paper III included counselling and psychotherapy with different time 
frames and settings (individual child or adolescent, group, parents, family, network). 
There are, however, no data in Pastill about which specific psychotherapeutic method 
has been used. Medication information is restricted to whether the drug is a central 
stimulant or not.  
Axis V, global functioning, is rated with CGAS before and after given treatment. 
Clinicians are instructed to rate the lowest level of functioning during the last month. 
In addition to entering CGAS ratings at intake, the clinicians make an overall 
assessment of the treatment outcome and also report the family’s/adolescent’s overall 
opinion of how the care has worked. This is rated on a 1-5 Likert scale where 
1=worsening of symptoms, 2=no change in symptoms, 3=symptoms are the same but 
easier to cope with, 4=improved symptoms, 5=no symptoms. The score -1 was chosen 
when the overall assessment was not possible to complete.  
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4.2.3 CGAS outcome measure, 
Paper III 
∆CGAS, defined as the difference 
between CGAS at intake and CGAS 
at case closure, was used to assess the 
change in psychosocial functioning 
during the course of treatment in 
Paper III. Mean ∆CGAS was analysed 
in relation to diagnosis. Four 
diagnostic patient groups were 
selected for further study of baseline 
factors (CGAS score at baseline, sex, 
age, psychosocial stressors, diagnosis) 
and intervention factors (treatment 
provided, professional background of 
the clinician, number of 
appointments) potentially predictive of ∆CGAS. The diagnostic groups were mood 
disorder, ADHD, obsessive-compulsive disorder (OCD), and conduct disorder. 
4.2.4 Subjects in Paper III 
All cases between 1 July 2006 and 31 January 2010 with a longer treatment period than 
one month (n=25,121) were selected (Figure 4). They constituted 57% of all the 
registered cases (n=44,261) during this time period. From these, the following cases 
were excluded: 1) Those with CGAS rating=0 or a missing CGAS rating at baseline 
(n=10,020); 2) CGAS ratings=100 at baseline (n=4); 3) Those younger than 4 years old 
(n=244) and those older than 20 years of age (n=37); 4) Those who underwent inpatient 
care (n=278); 5) Those with CGAS rating=0 or missing at end point (n=1,925). 
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Only outpatients were included since the majority of inpatients (n=196 of 278) had 
shorter treatment periods than one month and the small remaining number of subjects 
(n=82) was not representative of the inpatient group as a whole. Hence, the total 
number of cases included in this study was 12,613. The included cases were between 4 
and 19 years old with a mean age of 12.0 years (SD=3.9). The group consisted of 6,012 
boys (47.7%) and 6,601 girls (52.3%).  
4.2.5 Statistical methods used in Paper III 
All statistical analyses in Paper III were conducted using PASW Statistics 19 (SPSS 
Inc., Chicago, Illinois, USA) or Statistica 9.0 (Statsoft Inc, Tulsa, Oklahoma, USA). 
Differences between the mean group scores of CGAS before and after treatment were 
tested using paired t-test. All tests were two-sided and p<0.05 was regarded as a 
statistically significant result.  
A stepwise multiple linear regression model was applied to estimate the contribution of 
each background and intervention variable on ∆CGAS. At each step, the independent 
variable not in the equation that had the smallest probability of F was entered, if that 
probability was sufficiently small (p<0.05). Variables already in the regression equation 
were removed if their probability of F became sufficiently large (p>0.10). The method 
terminated when no more variables were eligible for inclusion or removal. This method 
yielded a reduced set of variables from the larger set of predictors, eliminated 
unnecessary predictors, simplified data, and enhanced predictive accuracy.  
4.2.6 National registers, Paper IV 
All Swedish citizens and immigrants have a unique 10-digit identification number that 
makes it possible to link data across different national registers and birth or clinical 
12,508 Excluded patients 
CGAS=0 at case closure 
CGAS=0 at baseline 
CGAS=100 at baseline         4 
1,704 
25,121 Selected patients  
4,494 
12,613 Included outpatients 
CGAS missing at baseline  5,526 
Inpatients   278 
Age <4 or >20 years old   281 
CGAS missing at case closure 221 
 
 
Figure 4. Flow diagram, excluded and included patients. 
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cohorts. In Paper IV, the study population from Pastill clinical database was linked to 
the following Swedish national registers:  
i) The National Patient Register (NPR), maintained by the National Board of Health 
and Welfare contains main diagnosis and up to seven secondary diagnoses. The NPR 
contains all admissions to inpatient care since 1987 and all visits to specialized 
(medical doctor visits) outpatient care since 2001. The data in the register are collected 
once a year and cover both public and private health care since 2001. In addition to 
diagnoses, NPR also contains information on causes of morbidity or mortality, 
accidents, surgical procedure codes, and discharge dates. Diagnoses are coded 
according to the 9
th
 (1987–1996), and 10th editions (1997-) of the International 
Classification of diseases (ICD). The validity of the NPR is considered high for most 
diagnoses (Ludvigsson et al. 2011) including psychiatric diagnoses (Ekholm et al. 
2005; Sellgren et al. 2011). Discharges and outpatient care that occurred up to 31 
December 2009 were included in the study. 
ii) The Swedish Crime Register (maintained by the National Council of Crime 
Prevention), contains information on all criminal convictions in Sweden since 1973. 
The age of criminal responsibility is 15 years (i.e., individuals younger than that cannot 
be charged and convicted). The conviction data included all individuals who received 
custodial or non-custodial sentences and cases where the prosecutor decided to caution 
or fine. All crimes committed before 31 December 2009 were included in the study. 
iii) The Cause of Death Register (CDR, Statistics Sweden) maintains data on all deaths 
in Sweden since 1952, including date of death and causes of death. Death events 
occurring before 31 December 2009 were included in the study and the information 
was used to set the time at risk among those who died during the follow-up period.  
4.2.7 Study population and exposure assessment, Paper IV 
The first treatment period (longer than one month) of all patients registered in Pastill 
from 1 July 2006, who were at least 18 years old on 31 December 2009 and therefore at 
risk for the specified outcomes, was included in Paper IV. In all, 6,525 patients fulfilled 
these criteria of which 5,903 had valid CGAS scores at intake and 4,876 had valid 
scores at end-of-treatment (not ‘0’ or missing). Of these, the vast majority had received 
outpatient care, 4,661, and 215 had received inpatient care. 
We dichotomised the study group into those with end-of-treatment CGAS scores up to 
60 and those with scores above 60. This cut-off score was chosen based on previous 
research on the discriminant validity for CGAS establishing the cut-offs of 60/61 and 
70/71 (Shaffer et al. 1983; Bird et al. 1987; Bird et al. 1990). According to these 
studies, 60 points or lower can be considered a definite case, 61-70 a probable case, and 
above 70 a probable non-case. This categorisation has been used in several 
epidemiological prevalence studies of mental disorders to define cases and separate 
them from non-cases (Bird et al. 1993; Milne et al. 1995; Canino et al. 2004; Geller et 
al. 2008). 
4.2.8 Outcomes and covariates, Paper IV 
We assessed whether CGAS ratings at intake and end-of-treatment were related to 
criminal convictions, suicide attempts, psychiatric morbidity, and accidents in 
adulthood (from age 18 years) during a period of up to 18 months following the end of 
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treatment. More specifically, we studied associations to: any criminal offence, suicide 
attempt (ICD-10 codes X60-X84), depression (ICD-10 codes F32-F34), anxiety 
disorder (ICD-10 codes F40-F41), eating disorder (ICD-10 codes F50), schizophrenia 
(ICD-10 codes F20, F25), bipolar disorder (ICD-10 codes F30-F31), borderline 
personality disorder (ICD-10 code F60.3), alcohol/substance misuse and abuse (ICD-10 
codes F10-F19), and accidents (ICD-10 codes V01-X59). 
Pastill contains information on psychiatric morbidity in childhood (age 0-17 years). 
Thus, for each psychiatric outcome we were able to adjust for the corresponding 
diagnosis at intake (i.e., childhood morbidity) except for i) bipolar disorder that was not 
specified in Pastill during the study period, and ii) borderline personality disorder, 
which according to common practice rarely is diagnosed before the age of 18 years. For 
the outcome of criminal offence, we adjusted for ADHD, oppositional defiant disorder, 
and conduct disorder at intake. We also used CGAS at intake as a covariate for all 
associations. 
4.2.9 Statistical methods used in Paper IV 
All participants contributed person-time from study entry (the date of the CGAS 
assessment at end-of-treatment) until the date of the outcome event, death, or study end 
(31 December 2009), whichever came first. The association between childhood 
psychosocial functioning as rated with CGAS and outcomes (criminal conviction, 
psychiatric morbidity, and accidents) was measured by hazard ratios (HRs) with 95% 
confidence intervals (CIs), taking follow-up time into account. HRs were estimated 
from Cox regression models. We present unadjusted HRs and adjusted HRs (aHRs) for 
all outcomes. In addition to dichotomising procedure of CGAS ratings to below 61 and 
above 60, we also used a 10-point scale measure of CGAS in which 1-10 was 
transformed to 1, 11-20 to 2 etcetera up to 91-100 that was transformed to 10. 
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5 ETHICS 
The research plan for Papers I and II was submitted to the Regional Ethical Review 
Board in Stockholm. The Ethical Review Board concluded that the research did not 
require an ethics permit since the research did not include sensitive information about 
individuals. They had no objections to the research procedures (2006/286-31). 
Nevertheless, all participants (health care professionals employed by CAMHS) were 
informed orally and in writing, and they gave their consent by signing a written form.  
The Regional Ethical Review Board approved the research conducted in Paper III 
(2010/1214-31/2). All the data used in Paper III was anonymous and neither individual 
patients nor health care professionals can be identified or traced in the material. Only 
two researchers, M.F. and myself, had access to the data.  
The Regional Ethical Review Board approved the research conducted in Paper IV 
(2009/939-31/5). All the data used in Paper IV was anonymous and individual patients 
could not be identified or traced in the material. 
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6 RESULTS 
6.1 TABLE 3. OVERVIEW OF THE FOUR PAPERS 
 I II III IV 
R
es
ea
rc
h
 q
u
es
ti
o
n
s 
How reliable and 
accurate are 
CGAS ratings in a 
naturalistic setting 
with a 
heterogeneous 
group of 
clinicians? 
Is training provided 
by computer as 
effective as training 
seminars? Has 
either type of 
training effect over 
and above a 
comparison group? 
Is child 
psychiatric 
treatment-as-usual 
effective in terms 
of improved 
global function as 
measured by 
CGAS? 
Can CGAS 
ratings predict 
future mental 
health disorders, 
and criminality? 
S
tu
d
y
 d
es
ig
n
 
Cross-sectional 
study  
Randomised 
comparison of 
training 
programmes, non-
randomised 
comparison group 
Prospective 
follow-up study 
Prospective 
follow-up study 
R
es
u
lt
s 
Clinicians rated 
vignettes 
significantly 
higher than 
experts. ICC= 
0.73. Social 
workers and 
psychologists 
were significantly 
more likely to 
have overall 
aberrant ratings 
than medical 
doctors. 
No differences were 
seen in training 
effects between 
computer-based 
training and 
seminars. The 
improvement was 
modest in both 
active groups. The 
comparison group 
improved by the 
same order of 
magnitude.  
For mood 
disorders, several 
psychotherapies 
were associated 
with better 
outcome but not 
medication. For 
ADHD, 
medication with 
central stimulants 
was not associated 
with better 
outcome. 
CGAS≤60 at 
end-of-treatment 
was significantly 
associated with 
higher risk of 
criminality, 
bipolar disorder 
and borderline 
personality 
disorder. 
C
o
n
cl
u
si
o
n
s 
The reliability and 
accuracy of 
CGAS ratings in 
clinical settings is 
moderate without 
prior training. 
The results speak in 
favour of using the 
less resource 
demanding 
computer-based 
training. However, 
the overall training 
effect was too small 
to be clinically 
relevant.  
The improvement 
of CGAS after 
treatment-as-usual 
differs from RCTs 
especially in 
ADHD. The 
results from 
clinical trials 
cannot be 
extrapolated to 
routine care.  
CGAS ratings at 
end-of-treatment 
provide specific 
long-term 
prognostic 
information. 
Attention should 
be given to 
patients with a 
CGAS rating 
≤60 at end-of-
treatment. 
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6.2 CGAS RATINGS IN A LARGE NATURALISTIC SETTING, PAPER I  
Paper I surveyed the reliability and validity of CGAS ratings in a large group of 
clinicians. 
6.2.1 Comparisons with expert ratings 
Table 4 shows that the untrained raters’ mean and median scores were significantly 
higher than the expert rating for all five cases (t-value 22.4-45.4, p<0.001). The range 
of between-rater scores (min-max) was wide for all 5 cases. The expert raters had a 
narrower range of scores. 
Table 4. Results from the rating of five written case vignettes. 
 Expert raters 
n=5 
 Untrained raters 
n=703
1
 
 Mean (SD) Median 
(Min-Max)  
Expert 
rating
2
 
 
Mean (SD) 
Median 
(Min-Max) 
Case A 14.2 (9.9) 12 (3-30) 9 22.0 (13.4) 20 (1-71) 
Case B 24.8 (1.8) 25 (22-27) 25 36.4 (12.5) 38 (8-80) 
Case C 46.5 (5.2) 45 (42-54) 45 62.7 (10.4) 63 (31-86) 
Case D 62.5 (3.0) 64 (58-64) 64 71.0 (8.2) 72 (48-94) 
Case E 51.2 (2.9) 51(48-55) 51 60.5 (11.2) 60 (6-91) 
1 
One participant did not rate case E.  
2 
The expert rating was established in a consensus discussion among the experienced 
raters after their individual ratings. 
6.2.2 Inter-rater reliability 
The ICC was 0.73 for “rater-to-rater” agreement in the untrained group. In the group 
with expert raters, the ICC was 0.92. The measurement error was estimated to be 11.3 
for untrained raters and 5.2 for experts.  
6.2.3 Aberrant ratings 
Table 5 shows that psychologists, social workers, and other staff members were twice 
as likely to score all cases aberrantly as medical doctors. Clinical experience or earlier 
experience of using CGAS had no statistically significant impact on aberrant ratings, 
whereas having no experience of GAF increased the risk of aberrant ratings compared 
to those who were very experienced GAF-users. Sex and age also affected the ratings in 
the present study: older raters and men had an increased likelihood of being overall 
aberrant raters.  
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Table 5. Odds ratio for the likelihood of an overall aberrant rating
1
 compared to expert 
ratings for the respective groups.  
 OR (95% CI) Overall 
aberrant rating 
n (%) 
Not overall 
aberrant 
rating n (%) 
Total  197 (28) 506 (72) 
Age 1.03* (1.01-1.05)   
Sex    
   Female  1.00 152 (27) 414 (73) 
   Male 1.53* (1.00-2.32) 45 (33) 92 (67) 
Work Experience    
   <2 years 1.54    (0.85-2.79) 38 (30) 90 (70) 
   2-10 years 1.46    (0.93-2.30) 59 (29) 145 (71) 
   >10 years 1.00 100 (27) 271 (73) 
CGAS experience    
   No experience 1.26    (0.83-1.91) 151 (30) 345 (70) 
   Experienced 1.00 46 (22) 159 (78) 
GAF experience    
   No experience 1.62*  (1.00-2.63) 67 (34) 133 (66) 
   Moderately 
   experienced 
1.21    (0.72-2.03) 42 (26) 123 (74) 
   Fairly experienced 1.28    (0.77-2.13) 40 (29) 97 (71) 
   Very experienced 1.00 48 (24) 151 (76) 
Occupation    
   Medical Doctor 1.00 15 (16) 77 (84) 
   Psychologist 1.91*   (1.01-3.59) 78 (27) 207 (73) 
   Social worker 2.46** (1.26-4.80) 57 (34) 112 (66) 
   Other staff members 2.04*   (1.04-4.02) 47 (30) 110 (70) 
1
 Overall aberrant rating was defined as more than ±5 points deviation from the expert 
ratings for all rated cases 
* significant at 0.05 level, ** significant at 0.01 level 
 
6.3 THE EFFECT OF RATER TRAINING, PAPER II 
Paper II studied the training effect of two training methods, live seminar and CD-ROM. 
6.3.1 Inter-rater reliability 
With respect to inter-rater reliability, the ICC values at baseline/end-of-study were 
0.71/0.78 in the seminar group, 0.76/0.78 in the CD-ROM group, and 0.67/0.79 in the 
comparison group. Measurement errors at baseline/end-of-study were 11.3/9.9 in the 
seminar group, 10.8/10.2 in the CD-ROM group, and 12.2/10.1 in the comparison 
group. The ICC and measurement errors after training suggest a minor improvement 
  37 
after training. The comparison group’s improvement was at the same order of 
magnitude as the groups with active training. 
6.3.2 Comparison of seminar and computer-based training  
There were no significant differences between the effects of the two forms of training, 
seminar and CD-ROM. Even though the improvement in ratings from baseline to end-
of-study was statistically significant in both groups, the effect was small and not 
clinically relevant in either group (Table 6). 
 
Table 6. Comparing seminar and computer-based training, cases A-E. 
C
as
e 
E
x
p
er
t 
ra
ti
n
g
 SEMINAR
1 
CD-ROM
2
 Unpaired t-test 
Mean (SD) 
change
4
  
end-of-
study 
P value
3
  
end-of-
study 
Mean (SD) 
change
4
  
end-of-
study 
P value
3
  
end-of-
study 
P value  
between  
groups  t-
v
al
u
e 
df 
C
h
an
g
e 
 
A
1
 -
 A
2
 
9 -4.0 (15.0) <0.001 -2.3 (15.2)   0.017 0.20 -1.3 529 
C
h
an
g
e 
 
B
1
 -
 B
2
 
25 -6.0 (13.3) <0.001 -3.9 (13.5) <0.001 0.066 -1.8 530 
C
h
an
g
e 
 
C
1
 -
 C
2
 
45 -1.6 (13.7)   0.049 -1.6 (11.3)   0.030 0.97 -0.04 528 
C
h
an
g
e 
 
D
1
 -
 D
2
 
64 -2.4 (10.0) <0.001 -2.3 (9.5) <0.001 0.96 -0.1 531 
C
h
an
g
e 
 
E
1
 -
 E
2
 
51 -5.3 (12.9) <0.001 -5.4 (12.1) <0.001 0.93 0.1 528 
1 
Seminar group n= 285 (Case A, B and D), n=284 (Case C), n=283 (Case E) 
2 
CD-ROM group n= 248 (Case D), n=247 (Case B, C and E), n=246 (Case A) 
3
 Ho: No change between baseline and end-of-study.  
4 
Mean change <0, the raters have improved and are coming closer to expert ratings 
6.3.3 No overall effect of training 
Data were pooled from the two training groups in order to study the effect of training as 
a whole. (For further details see Paper II.) Although the merged training group 
improved significantly on all five cases, compared to improvements on only two out of 
five cases in the comparison group, there were nonetheless no differences that reached 
statistical significance between the training group and the comparison group in end-of-
study ratings (Table 7).  
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Table 7. Difference between (baseline rating—expert rating) and (end-of-study 
rating—expert rating). 
 Training  
groups
1
 
Comparison 
group
2
 
Paired t-test 
 Mean (SD) 
change
3
  
end-of-study 
Mean (SD) 
change
3
  
end-of-study 
P value  
between 
groups 
t-value df 
Mean all 
cases 
-3.5 (7.7) -3.4 (7.6) 0.93 -0.1 572 
A1-A2 -3.2 (15.1) -5.7 (13.1) 0.29 1.1 574 
B1-B2 -5.0 (13.4) -5.4 (13.8) 0.86 0.2 575 
C1-C2 -1.6 (12.6) -0.6 (12.3) 0.63 -0.5 574 
D1-D2 -2.3 (9.7) -2.0 (11.2) 0.80 -0.3 576 
E1-E2 -5.4 (12.5) -3.4 (14.1) 0.32 -1.0 573 
1 
Training groups(CD-ROM and seminar) n=533 (case D) 532 (case B) 531 (cases A, 
C) 530 (case E) 
2 
Comparison group n=45 
3 
A mean change <0 corresponds to rater improvement, that is, a change in the 
direction of the expert rating 
 
6.3.4 Trainee satisfaction 
Just over one third (241/648) of the participants responded to a web questionnaire 
regarding their satisfaction with the training they had performed. By and large, the 
participants were satisfied with both types of training, though those who attended the 
seminar were slightly more satisfied. On a scale of 1-6 where 6 corresponds to the 
highest level of satisfaction, the mean grade for the seminar was 5.4 and for the CD-
ROM 4.9. 
6.4 EFFECTIVENESS OF CHILD PSYCHIATRIC TREATMENT, PAPER III 
In Paper III, the effectiveness of child psychiatric treatment was studied by evaluating 
the change in psychosocial functioning as measured by CGAS in a group who received 
outpatient care in Stockholm County between 2006 and 2010.  
6.4.1 Diagnostic categories  
The three most common diagnoses were anxiety disorder, mood disorders and ADHD. 
Table 8 lists mean CGAS ratings at baseline and ∆CGAS for all diagnoses. The mean 
CGAS ratings improved (mean ∆CGAS>0) during the course of care across all 
diagnostic groups. Patients with mental retardation showed the lowest improvement in 
global functioning with a mean ∆CGAS of 3.9. Those who had attempted suicide and 
received treatment in outpatient settings showed the highest change in CGAS with a 
mean ∆CGAS of 16.1.  
Patients with mood disorders and ADHD had similar mean CGAS ratings at baseline 
(50.3 and 50.5), whereas the improvement at end-of-study differed significantly: those 
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with mood disorders had a mean improvement of 13.4 points, but those with ADHD a 
mean improvement of only 6.5 points. 
 
Table 8. Diagnostic category, baseline CGAS rating and ΔCGAS at end-of-treatment. 
Diagnostic category n= Baseline ΔCGAS1 Paired t-test  
   Mean (SD) Mean (SD) t-value* df 95% C.I. 
Suicide attempt 302 43.5 (9.9) 16.1 (14.5) 19.4 301 14.5, 17.8 
OCD 606 49.4 (9.7) 14.1 (13.3) 26.1 605 13.0, 15.2 
Somatoform disorder 71 51.3 (10.0) 14.0 (14.6) 8.1 70 10.5, 17.4 
Mood disorders  2,213 50.3 (9.8) 13.4 (12.2) 51.7 2,212 12.9, 13.9 
Anxiety disorder 2,446 51.3 (10.2) 13.2 (11.9) 54.7 2,445 12.7, 13.7 
Identity problem 529 51.6 (10.3) 11.9 (11.1) 24.7 528 10.9, 12.8 
Eating disorder 613 48.2 (11.3) 11.8 (12.8) 22.8 612 10.8, 12.8 
Sleep disorder 605 49.4 (11.1) 11.7 (11.7) 24.5 604 10.7, 12.6 
PTSD 440 52.4 (9.3) 11.6 (12.5) 19.4 439 10.4, 12.7 
Dissociative disorder 76 45.8 (11.8) 11.6 (13.7) 7.3 75 8.4, 14.7 
Psychotic disorder 23 41.4 (9.0) 11.1 (10.9) 4.9 22 6.4, 15.8 
Gender identity 
disorder 
28 50.5 (9.6) 10.8 (11.2) 5.1 27 6.5, 15.2 
Other 1,553 59.1 (8.8) 10.8 (9.3) 45.8 1,552 10.3, 11.2 
Enuresis 75 51.4 (12.0) 10.5 (11.4) 7.9 74 7.9, 13.1 
Drug related disorder 78 47.2 (9.3) 9.7 (12.3) 7.0 77 7.0, 12.5 
No observed 
symptoms 
169 67.1 (12.0) 9.7 (10.4) 12.2 168 8.1, 11.3 
Encopresis 100 53.5 (10.8) 9.5 (10.2) 9.3 99 7.5, 11.5 
Oppositional defiant 
disorder 
643 51.4 (8.8) 9.3 (10.0) 23.5 642 8.5, 10.0 
Conduct disorder 390 50.1 (10.2) 8.8 (10.5) 16.6 389 7.8, 9.9 
Reactive attachment 
disorder 
10 46.1 (6.3) 8.8 (10.4) 2.7 9 1.3, 16.3 
Lack of information 1,690 56.5 (10.5) 8.2 (9.6) 34.8 1,689 7.7, 8.6 
Tic disorder 151 52.9 (10.0) 8.0 (8.3) 11.9 150 6.7, 9.4 
Eating disorder, infant 19 53.9 (9.6) 7.8 (12.2) 2.8 18 1.9, 13.7 
Motor skills disorder 63 46.9 (11.2) 7.4 (11.0) 5.3 62 4.6, 10.2 
Learning disorder 445 50.3 (9.3) 6.8 (9.4) 15.2 444 5.9, 7.6 
ADHD 1,169 50.5 (9.5) 6.5 (8.9) 25.0 1,168 6.0, 7.1 
Communication 
disorder 
404 47.7 (11.2) 5.4 (8.3) 13.1 403 4.6, 6.2 
Pervasive 
developmental 
disorder 
1,053 45.0 (10.3) 4.3 (8.5) 16.6 1,052 3.8, 4.8 
Mental retardation 224 41.2 (14.0) 3.9 (9.6) 6.2 223 2.7, 5.2 
1ΔCGAS=CGAS at end-of-treatment minus CGAS at baseline. 
*all differences were significant at 0.001 level. 
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6.4.2 Correlation between ∆CGAS and overall assessment of treatment 
response 
There was a moderate correlation between ∆CGAS and the assessment of treatment 
response made by the managing clinician after final visit (r=0.47, p <0.001).  
6.4.3 Outcome predictors  
A complete table is displayed in Paper III of all the variables from the stepwise 
regression that had an F-value with a probability of less than 0.05. A higher CGAS 
baseline rating was predictive of lower ∆CGAS across all four diagnostic groups - 
mood disorder, ADHD, conduct disorder and obsessive compulsive disorder - which is 
in line with other studies (Wiggins et al. 2010; Setoya et al. 2011). Also, a higher 
number of diagnoses (comorbidity) was associated with lower ∆CGAS in all groups 
except conduct disorder.  
Taken as a whole, the diverse psychotherapies offered within CAMHS to patients with 
mood disorders predicted improvement of CGAS ratings, whilst there was no 
significant positive effect from medication. For patients with ADHD, the number of 
appointments, the use of group parent counselling, and having a physician manage the 
cases were all predictors of improvement, whereas treatment with central stimulants 
was not. Two family-oriented treatments were positive predictors of outcome among 
those with conduct disorder (group counselling for parents and family therapy). 
Psychotherapy also led to improved CGAS scores for those with OCD, whereas 
guidance to parents predicted less improvement in CGAS.  
To better understand the lack of significant positive effect of central stimulants in 
ADHD, those treated with central stimulants were compared post hoc with the ADHD 
cases where no central stimulants were prescribed (Table 9).  
 
  
  41 
Table 9. Background and intervention variables in ADHD with or without central 
stimulants (n=1,169
1
). 
  
  
Central 
stimulants 
n=132 
No central 
stimulants 
n=910 
Unpaired t-test  
  Mean (SD) Mean (SD) P value t-value df 
Age 13.3 (3.5) 11.0 (3.8) <0.001 -6.6 1,040 
Number of diagnoses 1.9 (1.1) 1.9 (1.1) 0.84 0.2 1,040 
Number of psychosocial 
stressors 
1.8 (1.3) 2.2 (1.7) 0.008 2.7 1,039 
CGAS at baseline 52.2 (9.5) 50.3 (9.6) 0.038 -2.1 1,040 
Number of visits 14.8 (13.8) 13.9 (13.8) 0.50 -0.7 1,040 
ΔCGAS2 7.1 (10.0) 6.4 (8.9) 0.38 -0.9 1,040 
  
N (%) N (%) P Value 
Pearson 
Chi-2 
df 
Sex      
 Boys 95 (72.0) 658 (72.3) 0.94 0.01 1 
 Girls 37 (28.0) 252 (27.7) 0.94 0.01 1 
Treatment intervention      
 Guidance to parents 82 (62.1) 707 (77.7) <0.001 15.2 1 
 Guidance to teenagers 47 (35.6) 363 (39.9) 0.35 0.9 1 
 Family 
therapy/counselling 
19 (14.4) 299 (32.9) <0.001 18.5 1 
 Teenage psychotherapy 5 (3.8)   32 (3.5) 0.88 0.02 1 
 Social network 
counselling 
9 (6.8) 102 (11.2) 0.13 2.3 1 
 Cooperation counselling 0   22 (2.2) 0.086 3.0 1 
 Group treatment, 
child/adolescent 
2 (1.5)   29 (3.2) 0.29 1.1 1 
 Child psychotherapy 1 (0.8)     4 (0.4) 0.62 0.2 1 
 Short term 
psychotherapy 
child/adolescent 
4 (3.0)   18 (2.0) 0.43 0.6 1 
 Interaction treatment 1 (0.8)   12 (1.3) 0.59 0.3 1 
 Medication, excluding 
central stimulants 
19 (14.4)   32 (3.5) <0.001 29.3 1 
 Therapeutic summer 
camp 
1 (0.8)    3 (0.3) 0.46 0.6 1 
 Environmental therapy 0    8 (0.9) 0.28 1.2 1 
 Unspecified treatment 9 (6.8)  42 (4.6) 0.27 1.2 1 
 No treatment 0  33 (3.6) 0.026 4.9 1 
1
Missing data about treatment intervention, n=127 cases 
2
Difference between CGAS rating at baseline and CGAS rating at end-of-treatment 
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This comparison showed that the group receiving central stimulants was older at the 
beginning of the treatment and had a two point higher CGAS baseline rating (that is 
were less functionally impaired) than those in the group that did not receive medication. 
There was no difference between the groups in number of diagnoses, number of visits 
or ΔCGAS. Treatment intervention differed not only with central stimulants. The group 
without central stimulants received more psychotherapeutic interventions such as 
guidance to parents and family therapy than the ADHD group who were treated with 
central stimulants. 
6.5 CGAS RATINGS AS PREDICTORS OF FUTURE MENTAL HEALTH, 
PAPER IV  
In Paper IV, we tested whether CGAS ratings at end-of-treatment predicts future 
negative outcomes in young adults. In total, 4,876 patients with valid CGAS data at the 
end-of-treatment were included in this prospective follow-up study (Table 10).  
 
Table 10. Intake characteristics of individuals with CGAS≤60 at end-of-treatment and 
controls with CGAS>60 at end-of-treatment. 
Characteristics at intake CGAS≤60 at  
end-of-treatment 
 (n = 2,260) 
CGAS>60 at  
end-of-treatment 
 (n = 2,616) 
Sex   
  Boys    868 (38.4%)     902 (34.5%) 
  Girls 1,392 (61.6%)  1,714 (65.5%) 
Age   
  Average age at end-of-treatment 
(SD) 
     16.5 (0.9)      16.5 (0.9) 
Childhood psychiatric morbidity   
  ADHD    116 (5.1%)       62 (2.4%) 
  Oppositional defiant disorder      50 (2.2%)       28 (1.1%) 
  Conduct disorder      45 (2.0%)       23 (0.9%) 
  Suicide attempt      47 (2.1%)       55 (2.1%) 
  Mood disorder    320 (14.2%)     524 (20.0%) 
  Anxiety disorder    252 (11.2%)     386 (14.8%) 
  Eating disorder    106 (4.7%)     126 (4.8%) 
  Psychotic disorder        3 (0.1%)         2 (0.1%) 
  Substance misuse      34 (1.5%)       15 (0.6%) 
CGAS at intake   
  ≤60   2,173 (98.3%)  1,271 (49.9%) 
  >60      38 (1.7%)  1,268 (50.1%) 
  Mean rating (SD)      47.4 (9.5)       60.3 (10.9) 
 
The study group was dichotomised into one group with end-of-treatment CGAS ratings 
of 60 and lower (n=2,260) and a second group with CGAS ratings above 60 (n=2,216). 
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The proportion of girls and boys, as well as the average age, did not differ between the 
two groups. The frequency of ADHD, conduct disorder, oppositional defiant disorder, 
and substance misuse was higher among those with CGAS 60 or lower, whereas mood 
disorder and anxiety disorder were more common in the higher than CGAS 60 group. 
Perhaps unsurprisingly, those who had CGAS≤60 at end-of-treatment also had lower 
CGAS ratings at intake. The follow-up time to first event after end-of-treatment ranged 
from 1 to 1½ years.  
To examine whether CGAS at end-of-treatment predicted adversities, we conducted a 
series of Cox regression analyses. Table 11 summarizes the HRs for the outcome 
variables in the group with CGAS≤60 at end-of-treatment compared to the group with 
CGAS>60 at end-of-treatment as reference. Table 11 also shows the HRs for the 
outcome variables based on 10-point intervals on the CGAS.  
The risk of criminal conviction was more 
than twice as high (HR 2.1, 95%CI 1.4-
3.2) for those with CGAS≤60 at end-of-
treatment compared to those with end-of-
treatment CGAS scores above 60. In fact, 
all adult adverse outcomes except for 
accidents were more likely to occur in 
the CGAS≤60 at end-of-treatment group, 
with unadjusted HRs ranging from 1.9 
for substance misuse to 11.7 for 
borderline personality disorder. The same 
pattern was seen in the 10-point measure 
of CGAS; where CGAS ratings were 
related to all adverse outcomes in 
adulthood except accidents.  
HRs adjusted for age, sex, calendar year, 
and childhood psychiatric morbidity 
provide information on whether CGAS 
ratings add information over and beyond 
what can be inferred from these covariates alone. As shown in Table 11, the aHRs 
remained increased for all outcomes and significant with respect to criminal 
convictions, bipolar disorder, and borderline personality disorder, suggesting that 
CGAS ratings at end-of-treatment provide specific prognostic information for these 
conditions. The 10-point measure of CGAS yielded a similar pattern of association with 
the outcomes: in addition, CGAS scores also correlated with depression and 
schizophrenia at levels of statistical significance. 
 
   
Table 11. Risk of adversities among child psychiatry patients in Sweden 1 July 2006-31 December 2009 with CGAS end-of-treatment ≤60 vs >60. 
 CGAS end-of-treatment ≤60 versus CGAS end-of-treatment >60  CGAS end-of-treatm: 10-point interval 
Outcomes Events, n= 
CGAS≤60 
vs >60 
Outcome incident rate per  
1000 person-years  
(95% CI) 
Unadjusted 
HR 
(95% CI) 
Adjusted 
HR
a
 
(95% CI) 
Adjusted 
HR
ab
 
(95% CI) 
Unadjusted 
HR 
(95% CI) 
Adjusted 
HR
a
 
(95% CI) 
Adjusted 
HR
ab
 
(95% CI) 
n
1
=2,260/n
2
=2,616 CGAS≤60 CGAS>60       
Crime 60/36 18.8 
(14.6-24.3) 
9.1 
(6.6-12.7) 
        2.1  *** 
(1.4-3.2) 
      1.8
c
  * 
(1.1-3.0) 
       2.4
c
  ** 
(1.2-4.8) 
       1.2   ** 
(1.1-1.4) 
       1.3
c    
** 
(1.1-1.5) 
      1.4
c
    * 
(1.1-1.8) 
Suicide attempt 24/8 7.5 
(5.0-11.1) 
2.0 
(1.0-4.0) 
      3.8   ** 
(1.7-8.4) 
1.5
d 
(0.5-5.0) 
1.1
d 
(0.3-4.0) 
      1.5  *** 
(1.2-1.8) 
1.3
d 
(0.8-1.9) 
1.1
d 
(0.7-1.9) 
Depression 59/29 18.6 
(14.4-24.0) 
7.3 
(5.1-10.6) 
       2.6   *** 
(1.6-4.0) 
1.6
e 
(0.9-2.8) 
1.5
e 
(0.8-2.8) 
      1.4  *** 
(1.2-1.6) 
    1.3
e   
* 
(1.1-1.5) 
1.2
e 
(1.0-1.6) 
Anxiety disorder 52/26 16.3 
(12.4-21.4) 
6.6 
(4.5-9.7) 
      2.6 *** 
(1.6-4.1) 
1.5
f 
(0.8-2.9) 
1.3
f 
(0.6-2.9) 
      1.4  *** 
(1.2-1.6) 
1.2
f 
(1.0-1.5) 
1.2
f 
(0.9-1.5) 
Eating disorder 11/4 3.4 
(1.9-6.2) 
1.0 
(0.4-2.7) 
      3.4    * 
(1.1-10.6) 
2.7
g 
(0.6-11.5) 
8.1
g 
(0.9-74.0) 
   1.4   * 
(1.1-1.9) 
1.4
g 
(0.9-2.2) 
1.9
g 
(0.9-3.8) 
Schizophrenia 6/0 1.9 
(0.8-4.1) 
N/A N/A N/A N/A         2.6  *** 
(1.6-4.0) 
    5.6
h
   * 
(1.2-26.2) 
N/A 
Bipolar disorder 20/4 6.2 
(4.0-9.6) 
1.0 
(0.4-2.7) 
        6.3   *** 
(2.2-18.5) 
      6.0   ** 
(2.0-17.7) 
      4.7   * 
(1.2-17.7) 
        1.6   *** 
(1.3-2.0) 
     1.6  *** 
(1.2-2.0) 
1.2 
(0.8-1.7) 
Borderline 
personality disorder 
19/2 5.9 
(3.8-9.3) 
0.5 
(0.1-2.0) 
      11.7  *** 
(2.7-50.7) 
      11.5  ** 
(2.7-49.8) 
      15.7  ** 
(2.2-113.0) 
         1.9   *** 
(1.5-2.4) 
     1.9  *** 
(1.5-2.4) 
1.4 
(0.9-2.3) 
Substance misuse 43/28 13.4 
(10.0-18.1) 
7.1 
(4.9-10.3) 
      1.9  ** 
(1.2-3.1) 
1.4
i 
(0.7-2.6) 
1.2
i 
(0.6-2.5) 
         1.3   *** 
(1.1-1.5) 
1.2
i 
(1.0-1.5) 
1.1
i 
(0.9-1.5) 
Accidents 
 
41/45 12.8 
(9.4-17.3) 
11.4 
(8.5-15.3) 
1.1 
(0.7-1.7) 
1.0 
(0.7-1.6) 
0.8 
(0.5-1.4) 
 1.1 
(0.9-1.2) 
1.1 
(0.9-1.2) 
1.0 
(0.8-1.2) 
Adjusted for 
a 
age, sex, and, calendar year 
b 
CGAS at intake, 
c 
childhood ADHD, conduct disorder and oppositional defiant disorder, 
d
 childhood 
suicide attempt, 
e
 childhood mood disorder, 
f
 childhood anxiety disorder, 
g
 childhood eating disorder 
h
 childhood psychotic disorder, 
i
 childhood 
substance misuse 
* Significant at 0.05 level, ** Significant at 0.01 level, *** Significant at 0.001 level 
n
1
 number of patients with CGAS at end-of-treatment ≤60, n2 number of patients with CGAS at end-of-treatment >60
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As shown in Table 10, CGAS 
ratings at intake were lower 
among those with CGAS≤60 at 
end-of-treatment. This first 
raises the question of whether 
the predictive value of end-of-
treatment CGAS ratings can be 
explained by CGAS at intake. 
However, adjusting for CGAS 
at intake revealed that CGAS at 
end-of-treatment is an 
independent predictor of these 
adult adversities (Table 11). For 
example, after adjusting for all 
covariates including CGAS at 
intake the risk for criminal 
conviction was still increased 
with 2.4 (1.2-4.8) for the 
patients with low CGAS at end-
of-treatment. 
A second question is whether CGAS ratings at intake might also be an independent 
predictor of adult adversities. To explore this, the analyses in Table 11 were repeated 
using CGAS ratings at intake as the explanatory variable instead of end-of-treatment 
CGAS. Table 12 shows the results of these analyses. There were 5,903 patients with 
valid CGAS ratings at intake of which 4,402 scored 60 or lower, and 1,501 scored 
above 60. The follow-up time to first event after intake ranged from 1½ to 2 years. 
Patients with CGAS≤60 at intake had an increased risk (unadjusted HRs) for suicide 
attempt, depression, anxiety disorder, and bipolar disorder compared to patients with 
CGAS>60 at intake. However, all these associations declined substantially when 
adjusted for age, sex, calendar year, and childhood psychiatric morbidity, leaving only 
bipolar disorder as statistically significant. However, the association between CGAS at 
intake and bipolar disorder also declined and was statistically non-significant when 
adjusting for CGAS at end-of-treatment. Similar patterns of associations were observed 
when we used the 10-point measure of CGAS at intake. This suggests that CGAS at 
intake does not predict adult adversities independent of age, sex, calendar year, 
childhood psychiatric morbidity and CGAS at end-of-treatment. 
   
Table 12. Risk of adversities among child psychiatry patients in Sweden 1 July 2006-31 December 2009 with CGAS intake ≤60 vs >60. 
 CGAS intake ≤60 versus CGAS intake >60  CGAS intake: 10-point interval 
Outcomes Events, n= 
CGAS≤60 
vs >60 
Outcome incidence rate per 
1000 person-years 
(95% CI) 
Unadjusted 
HR 
(95% CI) 
Adjusted 
HR
a
 
(95% CI) 
Adjusted 
HR
ab
 
(95% CI) 
Unadjusted 
HR 
(95% CI) 
Adjusted 
HR
a
 
(95% CI) 
Adjusted 
HR
ab
 
(95% CI) 
n
1
=4,402/n
2
=1,501 CGAS≤60 CGAS>60       
Crime 74/26 9.9 
(7.9-12.4) 
8.7 
(5.9-12.7) 
1.3 
(0.8-2.0) 
0.9 
(0.5-1.5) 
0.5
c
 
(0.2-0.9) 
 1.1 
(1.0-1.3) 
1.0
c
 
(0.8-1.3) 
0.7
c
 
(0.6-1.0) 
Suicide attempt 30/4 4.0 
(2.8-5.7) 
1.3 
(0.5-3.5) 
    3.1  * 
(1.1-8.9) 
2.1
d 
(0.5-9.8) 
1.7
d 
(0.3-9.0) 
        1.5  ** 
(1.1-1.9) 
1.3
d 
(0.8-2.2) 
1.0
d 
(0.5-2.1) 
Depression 78/14 10.4 
(8.3-13.0) 
4.7 
(2.9-8.1) 
      2.4  ** 
(1.4-4.2) 
1.5
e 
(0.7-2.8) 
0.9
e 
(0.4-2.0) 
         1.4  *** 
(1.2-1.6) 
1.2
e
 
(0.9-1.5) 
0.9
e 
(0.6-1.3) 
Anxiety disorder 66/14 8.8 
(6.9-11.2) 
4.7 
(2.8-7.9) 
    2.1  * 
(1.2-3.7) 
1.3
f 
(0.6-2.7) 
0.9
f 
(0.4-2.2) 
        1.3  *** 
(1.1-1.6) 
1.1
f 
(0.8-1.5) 
0.9
f 
(0.6-1.3) 
Eating disorder 10/3 1.3 
(0.7-2.5) 
1.0 
(0.3-3.1) 
1.4 
(0.4-5.1) 
0.8
g 
(0.2-4.4) 
0.2
g 
(0.0-2.0) 
 1.1 
(0.7-1.7) 
1.0
g 
(0.5-2.0) 
0.6
g 
(0.2-1.3) 
Schizophrenia 6/0 0.8 
(0.4-1.8) 
N/A N/A N/A N/A          2.4  *** 
(1.5-3.9) 
4.0
h
 
(0.9-16.6) 
N/A 
Bipolar disorder 22/2 2.9 
(1.9-4.4) 
0.7 
(0.2-2.7) 
      4.8  ** 
(1.1-20.6) 
   4.4  * 
(1.0-18.8) 
1.3 
(0.2-7.2) 
         1.8   *** 
(1.4-2.4) 
      1.9  *** 
(1.4-2.5) 
1.4 
(0.9-2.2) 
Borderline personality 
disorder 
17/2 2.3 
(1.4-3.6) 
0.7 
(0.2-2.7) 
3.5 
(0.8-15.0) 
3.2 
(0.7-14.0) 
0.5 
(0.1-3.1) 
         2.0   *** 
(1.5-2.7) 
      2.0  *** 
(1.5-2.8) 
1.3 
(0.7-2.2) 
Substance misuse 60/16 8.0 
(6.2-10.3) 
5.3 
(3.3-8.7) 
1.7 
(1.0-3.0) 
1.1
i 
(0.6-2.2) 
0.8
i 
(0.4-1.7) 
         1.4   *** 
(1.2-1.6) 
1.1
i 
(0.9-1.4) 
0.9
i 
(0.7-1.3) 
Accidents 
 
72/24 9.6 
(7.6-12.1) 
8.0 
(5.4-12.0) 
1.3 
(0.8-2.1) 
1.2 
(0.7-1.9) 
1.1 
(0.6-2.0) 
 1.1 
(0.9-1.3) 
1.0 
(0.9-1.2) 
1.0 
(0.8-1.2) 
Adjusted for 
a 
age, sex and, calendar year 
b 
CGAS at end-of-treatment, 
c 
childhood ADHD, conduct disorder and oppositional defiant disorder, 
 
d
 childhood suicide attempt, 
e
 childhood mood disorder, 
f
 childhood anxiety disorder, 
g
 childhood eating disorder 
h
 childhood psychotic disorder, 
 
i
 childhood substance misuse 
* Significant at 0.05 level, ** Significant at 0.01 level, *** Significant at 0.001 level  
n
1
 number of patients with CGAS at intake ≤60, n2 number of patients with CGAS at intake >60 
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7 GENERAL DISCUSSION 
7.1 INTER-RATER RELIABILITY 
Clinical researchers are especially interested in inter-rater reliability and I often get 
questions about the ICCs for CGAS ratings. High levels of inter-rater reliability suggest 
higher quality ratings, which minimises variability and results in less distortion of 
outcome measures, for example, in clinical trials (Rosen et al. 2008). 
The child psychiatric literature suggests that the ICC for rating instruments should be 
greater than 0.80 (Myers and Winters 2002), even though literature on rating scales 
cites varying acceptable levels of ICC, starting as low as 0.41 (Anastasi and Urbina 
1997; Shrout 1998; Renou et al. 2004). For comparison’s sake, intensive training in the 
use of the widely used Hamilton Depression Rating Scale (HDRS) led to an ICC above 
0.90. 
The present study found an ICC of 0.73, which according to Shrout’s standards falls 
into the range of moderate reliability (0.61-0.80). This result accords to previous 
smaller studies of CGAS in clinical settings that have found ICCs ranging from 0.53 to 
0.90 (Green et al. 1994; Rey et al. 1995; Dyrborg et al. 2000; Hanssen-Bauer et al. 
2007). In the expert group, however, the ICC reached 0.92, which corresponds to 
substantial inter-reliability. Together these findings suggest that, although the ICC 
would ideally be higher, CGAS is reliable enough to be used in clinical settings. 
It is known that the focus and characteristics of the case influence the reliability of 
CGAS ratings. This includes the child’s individual symptoms, diagnosis, family 
dynamics, or psychosocial risk factors. The inter-rater reliability in CGAS at two 
different time points has also been shown to show less agreement in cases with less 
severe emotional disorders than in cases with severe or more clear-cut single symptom 
disorders (Shaffer et al. 1983; Steinhausen 1987). In line with this reasoning, the range 
and distributions of the ratings in this study differed between the five rated cases (data 
not shown).  
7.2 VALIDITY AND THE BEST ESTIMATE FOR A GOLD STANDARD 
In contrast to the many inquiries about CGAS’s reliability I receive from clinicians, I 
seldom get questions about the scale’s validity. Establishing a rating scale’s validity is 
difficult: it usually takes several years, and is especially challenging because there is no 
natural gold standard for psychiatric instruments. Widely used older scales are, 
furthermore, seldom revalidated after their introduction (Myers and Winters 2002).  
Papers III and IV investigate different aspects of CGAS’ validity. The effectiveness 
study in Paper III found that the CGAS ratings in clinical practise was comparable with 
clinical trials and follow-up studies (Table 1), and thus support the validity of the scale.  
Paper IV found that CGAS has predictive validity for a number of adverse outcomes.  
For the purpose of Papers I and II, I chose to establish validity by allowing a group of 
experienced clinicians to together create a gold standard for the five cases I used. Of 
course these ratings are themselves contestable, but there is good reason to believe that 
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five experienced clinicians can reach a rating that can be considered a valid best 
estimate. Even though five experts may seem a small number, it is greater than the 
number of experts used to establish baseline ratings in previous studies of rating scales 
(Miller et al. 2003; Hanssen-Bauer et al. 2007).  
Both Paper I and the Hanssen-Bauer study showed that when a group does ratings they 
tend to be lower than when individuals rate cases alone (2007). Why would group 
discussion lead to lower ratings of functional impairment than individual ratings? Does 
the group member with the lowest rating persuade the others? Or are clinicians more 
likely to follow the instruction that the rating should reflect the lowest level of 
functioning when in a group? Probably both of these mechanisms are at work. 
Perhaps the most significant reason that raters in our studies deviated from the gold 
standard, virtually always setting a higher less functionally impaired score, was that 
they advertently or inadvertently violated the instructions. The instructions for using 
CGAS in our study followed Shaffer’s original instructions and are clear: Score the 
most impaired level of global psychosocial functioning during the last month (Shaffer 
et al. 1983). During seminars, however, some clinicians tried to explain away a low 
level of functioning as a product of circumstances, saying for example, “If this child did 
not live in this situation then he/she would function better in school.” In the same vein, 
some clinicians focused on the strengths and positive behaviours of the child instead of 
rating according to the lowest level of functioning.  
Professionals working with crisis intervention in particular found that focusing on a 
patient’s lowest level of functioning were at odds with the way they tend to work. Since 
they usually first meet children at a time of extreme functional impairment, these 
clinicians commonly experience a large drop in the child’s symptom burden after only 
a few days of treatment. Yet, if they would adhere to the CGAS’s instructions to rate 
the preceding month, the ratings at intake and at end-of-treatment a few days later 
would not reflect any improvement. The usage of the one-month time period for rating 
CGAS might be inappropriate in these settings, and that either another rating 
instrument, or using CGAS with a shortened time frame would be more useful.  
Surprisingly, given Shaffer’s original intentions for CGAS, other studies on CGAS 
have used numerous other time frames and various levels of functioning: for example, 
the highest level of functioning during a couple of months together with the average 
level of functioning during the last three weeks (Rey et al. 1995); the lowest level 
during the last three months (Dyrborg et al. 2000); the lowest level during the last week 
(Green et al. 1994); the average level during a whole lifetime (Weissman et al. 1990); 
the lowest level during the last two weeks (Hanssen-Bauer et al. 2007); the lowest level 
during the last four days (Szobot et al. 2004); and the current, the highest in the past, 
and the most severe in the past (Bella et al. 2011). It is also surprisingly common that 
studies fail to explain what rating strategy research subjects have been instructed to use 
(Table 1). Different rating instructions inevitably result in differences in the scale’s 
reliability and validity.  
7.2.1 Variation among raters 
Social workers, psychologists, and other staff members were significantly more likely 
to have overall aberrant ratings than medical doctors. This is in line with a previous 
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small study that found that experienced clinicians (n=3) had a better ICC than trainees 
in child and adolescent psychiatry (n=2) (Dyrborg et al. 2000), but these results contrast 
with other studies that have not found that clinical experience or occupational 
background affect ratings (Steinhausen 1987; Hanssen-Bauer et al. 2007). 
A possible explanation for this variation is that medical doctors have more training in 
collecting and merging clinical information into a short assessment and a preliminary 
diagnosis than psychologists and social workers have, a process similar to that needed 
to reach a CGAS rating.  
Sex and age also affected the ratings. Older raters and men had an increased likelihood 
of being overall aberrant raters. To my knowledge there are no previous studies on this 
issue. Some experienced clinicians explained to me before training sessions that they 
did not need to participate in the CGAS training because of their long clinical 
experience and the scale’s user-friendly construction. Maybe this attitude correlates 
with less motivation to heed the training instructions. A Swedish study has shown that a 
positive attitude towards another similar unidimensional scale, GAF, minimized 
measurement error and led to better reliability (Söderberg et al. 2005). A possible 
explanation for men’s tendency to have more aberrant ratings is that when the baseline 
ratings occurred, on average the male participants did not use the whole hour and 
delivered their results sooner than the female raters. From this anecdotal information 
one might hypothesize that spending more time and care on the ratings leads to more 
thoughtful and accurate ratings.  
7.3 THE EFFECTS OF DIFFERENT TRAINING METHODS 
Study II found that CGAS training in a “live” seminar is no more effective than 
computer-based training. Moreover, and perhaps more importantly, neither form of 
training led to clinically significant improvements in clinicians’ ability to use the scale 
accurately. Although the merged training group improved significantly on all five 
cases, compared to only two out of five cases in the comparison group, there were 
nonetheless no significant differences between the training group and the non-
randomised comparison group end-of-study ratings. As discussed above, the inter-rater 
reliability was also only moderate, in both the training groups and the control groups. 
Even though these findings are in line with a GAF training study where training did 
little to bring ratings closer to the established gold standard (Bates et al. 2002), this 
small training effect was a disappointment. 
In retrospect, when planning this study I took for granted that training leads to learning. 
CAMHS in Stockholm devotes more than 10% of its total budget to training activities, 
suggesting that faith in training’s effectiveness is widespread. This is despite recent 
research that has pointed out that educational activities are seldom evaluated for their 
effectiveness, only for how participants felt about them (Kirkpatrick and Kirkpatrick 
2005). This is consistent with my results, which showed widespread appreciation 
among participants of both forms of training, even though the same participants’ rating 
skills did not change enough to be of clinical relevance.  
There are two possible explanations for why we saw no significant effect from the 
trainings: that we tested participants too long after the training so that any effects had 
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waned, and that the comparison group was neither a randomly assigned control group, 
nor as large as the intervention groups. At the start of the study we planned to test 
participants six months after training. However, the number of included units increased 
and this delayed the end-of-study ratings by an additional six months. In the end, one 
year had lapsed between the time of training and the time of testing, and this may well 
explain the lack of any significant training effect. This hypothesis is supported by a 
recently published study on training of suicide prevention gatekeepers, which showed 
loss of actual skills, but not loss of knowledge and attitudes, over a three-month period 
(Cross et al. 2011). 
Because of the lack of a randomised and sufficiently large control group, the study’s 
results cannot be interpreted in the same manner as a randomised placebo-controlled 
clinical trial. It is striking that none of the previous studies that have evaluated training 
programmes for different rating scales included a control group, which makes it 
difficult to determine whether the improved results were the effects of training or an 
effect of non-specific factors (Bates et al. 2002; Kobak et al. 2003; Kobak et al. 2006; 
Kobak et al. 2007; Rosen et al. 2008). One conclusion to draw from the present results 
is that further research on educational activities should be designed as regular RCTs, 
and include randomly assigned control groups to control for the placebo improvement 
that might occur.  
Given the lack of differences in the outcomes of the two training methods, our study 
suggests that if future CGAS trainings are to be carried out they can use the more 
flexible and probably less resource-demanding computer based training method, easily 
adjusted for the Internet, and reachable for all mental health professionals in Stockholm 
and in Sweden.  
7.4 THE EFFECTIVENESS OF CHILD PSYCHIATRIC TREATMENTS AS 
MEASURED BY CGAS 
In Paper III, we used CGAS to measure treatment outcomes in child psychiatric 
outpatients with a range of psychiatric diagnoses. The change in CGAS ratings from 
intake to case closure generally reflected what a range of other studies have indicated 
about child psychiatric treatment. In large diagnostic groups such as mood disorders 
and ADHD, changes in CGAS ratings suggested that some established therapies may 
not be as effective as thought. 
Those with mental retardation showed the lowest improvement in global functioning 
with a mean ∆CGAS of 3.9. This should come as no surprise given the lack of effective 
treatment available for this group within CAMHS. In fact, this group receives most of 
their care and training within the school system. 
By contrast, patients who had attempted suicide and received treatment in outpatient 
settings showed the highest change in CGAS with a mean ∆CGAS of 16.1. This may 
indicate successful crisis intervention, but may also be the result of the natural 
reversion of the crisis and improvement of CGAS, known as regression towards the 
mean. This phenomenon was described already in the 19
th
 century and showed that 
extreme values tend to get closer to the mean value at the second measuring point. 
Adding a control group would be one way to control for this possible effect, but this is 
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not an option in such a large naturalistic study as this one. It should be noted that the 
suicide attempts included in this study were among the less severe, since more severe 
cases receive inpatient treatment and were therefore not included. 
7.4.1 Mood disorders 
The group with mood disorders improved 
with a mean ∆CGAS of 13.4. This size of 
improvement, as well as the level of 
baseline ratings, is almost identical with the 
results from previous efficacy studies of 
depressed adolescents (Wagner et al. 2003; 
March et al. 2004; Mufson et al. 2004; 
Wagner et al. 2006). Our results of 
CAMHS treatment as usual of mood 
disorders can also be compared with a 
large-scale clinical trial, the Treatment of 
Adolescent Depression Study (TADS). 
Compared to adolescents who had received what proved to be the most effective 
intervention in TADS – a combination of selective serotonin reuptake inhibitors (SSRI) 
and cognitive behavioural therapy (CBT) –  CAMHS patients were slightly less 
improved, but in the same range as the two other TADS intervention groups: the one 
that received only SSRIs or CBT, respectively (Vitiello et al. 2006). In a psychotherapy 
trial (Brent et al. 1997) comparing cognitive, family, and supportive therapy, the CGAS 
baseline was 4-8 points higher (less impaired) and the improvement for all groups 3-5 
points lower compared to Paper III. 
In contrast to the TADS study where SSRIs alone had almost the same effect as SSRIs 
combined with CBT, and CBT alone had almost no effect (March et al. 2006; Vitiello 
et al. 2006), we found that psychotherapy predicted improvement whereas medication 
did not. The results in Paper III are therefore at odds with the Swedish clinical 
guidelines on depression and anxiety disorder published (National Board of Health and 
Wellfare 2010), which are in part based on the 
results of the TADS study.  
7.4.2 ADHD 
Whereas the level of improvement in the mood 
disorder group by and large corresponded to 
previous efficacy studies, this was not the case 
in the ADHD group. First, the baseline rating 
in our study was 50.5, which is between 2 and 
12 points lower than baseline ratings in 
previous ADHD studies (Szobot et al. 2004; 
Preuss et al. 2006; Kratochvil et al. 2007; 
Findling et al. 2008; Berek et al. 2011). 
Second, the mean CGAS improvement in the 
ADHD group was only 6.5 points, which can be compared with three small efficacy 
studies in which the mean CGAS improvement ranged from 8.2 to 18.9 (Szobot et al. 
  52 
2004; Kratochvil et al. 2007; Findling et al. 2008). One of these, the MTA study, 
recruited a group of patients from a naturalistic population but there are unfortunately 
no CGAS ratings in that study to compare our results with (MTA Cooperative Group 
1999). Taken together, our results and previous studies suggest that ADHD patients in 
clinical trials are less impaired and improve more with treatment than do ADHD 
patients in a naturalistic study population. This means that the results of ADHD clinical 
trials cannot be generalised to the real world ADHD population.  
The treatment effectiveness of central stimulants has been the subject of intense 
discussion since the MTA 8 year prospective follow-up was published (Molina et al. 
2009). We found that central stimulants did not predict improvement in the ADHD 
group. Instead, factors that predicted better outcomes for ADHD patients were the 
number of appointments, group parent counselling, and that a physician managed the 
case.  
This finding prompted us to conduct a post hoc comparison between ADHD cases with 
and without central stimulants. This comparison showed that the group receiving 
central stimulants was older at the beginning of the treatment and had a two point 
higher CGAS baseline rating (less functionally impaired) compared with the group with 
no medication. Since the linear regression analysis revealed that higher age was 
positively associated with ∆CGAS, this age difference could not explain why treatment 
with central stimulants did not predict ∆CGAS. However, the regression analysis also 
revealed that a higher CGAS baseline rating was negatively associated with ∆CGAS. 
The group difference on CGAS at baseline might thus partially account for the fact that 
central stimulants did not predict ∆CGAS, even though the difference was only two 
points. 
More importantly, however, is that the ADHD cases that continued treatment – and 
therefore not included in the study due to the lack of a CGAS rating at case closure – 
differed significantly with respect to the higher frequency of treatment by central 
stimulants. One possibility is therefore that cases with a positive effect from central 
stimulants were more likely to stay in treatment and therefore more likely to be 
excluded from this study. There is also the possibility that the selection worked the 
other way around, that is, that those with poor treatment results tended to require longer 
treatment periods.  
The patients who received central stimulants also differed from those who did not 
receive medication with respect to other interventions. The non-medication group 
received more guidance to parents and more family therapy/counselling than the group 
with central stimulants. One possibility is therefore that this difference might have 
cancelled out any positive effect from central stimulants.  
We cannot settle these issues with the current data set, and our results with respect to 
the effect of central stimulants should therefore be treated with caution. These results 
should, however, also prompt a critical discussion about whether patients receive the 
best available treatment within CAMHS in Stockholm and elsewhere. 
Leaving the question of central stimulants’ effectiveness aside, our results lend support 
to clinical guidelines that recommend parent counselling/training, school support, and 
behavioural modification for patients with ADHD (National Institute for Health and 
Clinical Excellence 2008). 
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7.4.3 Conduct disorder 
Two family oriented treatments, group 
counselling for parents and family therapy, 
were positive predictors of outcome among 
those with conduct disorder. This is in 
agreement with available evidence that 
multi-systemic therapy is the treatment of 
choice for conduct disorder (Henggeler et al. 
1995). Even though patients with conduct 
disorder represented a small fraction of the 
total number, the group is important to 
identify and treat due to the association of 
conduct disorder with adversities in adulthood, including criminality (Fergusson et al. 
2005; Engqvist and Rydelius 2007; Sourander et al. 2007; Mordre et al. 2011) and 
psychiatric morbidity (Kim-Cohen et al. 2003; Olsson et al. 2006). The mean CGAS at 
baseline was 50.1 and the mean ∆CGAS was 8.8, leading to a mean CGAS at end-of-
treatment below 61. Unfortunately, we found in Paper IV that this post-treatment rating 
was associated with an increased risk of negative outcomes in early adulthood, 
especially criminal conviction, bipolar disorder, and borderline personality disorder 
(Paper IV). 
7.4.4 Obsessive-compulsive disorder 
For OCD patients, all individual 
psychotherapeutic interventions were associated 
with improvement in CGAS ratings, but 
guidance to parents was less effective. 
Medication was not associated with 
improvement according to CGAS ratings. Given 
the apparent effectiveness of a range of 
psychotherapeutic interventions for alleviating 
functional impairment due to OCD, one can 
hypothesize that CGAS would show even larger 
changes if CAMHS followed the guidelines 
established in the POTS study that single out CBT combined with SSRI as the most 
effective available treatment for OCD (Pediatric OCD Treatment Study (POTS) 2004; 
Franklin et al. 2011). 
7.5 THE PREDICTIVE VALUE OF CGAS RATINGS  
In Paper IV, 4,876 child psychiatric patients in late adolescence were followed 
prospectively over 1 to 1½ years. CGAS ratings along with other clinical data from the 
database Pastill were linked with national Swedish registers. Hazard ratios were 
calculated for criminal conviction, psychiatric disorders, drug misuse, and accidents in 
early adulthood. 
The results showed that CGAS ratings below 61 at end-of-treatment independently 
predicted criminal conviction, bipolar disorder, and borderline personality disorder in 
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early adulthood. This suggests that CGAS ratings contain prognostic information that 
can serve to guide clinical decision-making.  
CGAS ratings are commonly performed at intake and at end-of-treatment regardless of 
the length of the treatment period. If the goal is to yield as valid long-term prognostic 
information as possible, should CGAS be rated at intake or at end-of-treatment? To 
explore this, the end-of-treatment results were adjusted for CGAS ratings at intake. The 
significantly increased risk of criminal conviction, bipolar disorder, and borderline 
personality disorder remained among those with CGAS ratings below 61 at end-of-
treatment, suggesting that these ratings add prognostic information irrespective of 
CGAS ratings at intake. By contrast, further analyses found that CGAS ratings at intake 
were not in themselves predictive of later adversities. 
This conclusion is in line with a previous study that found no relationship between 
CGAS ratings at hospital admission and at place of residence (home vs long-term 
inpatient care/institution) one year after hospital discharge (Sourander et al. 1996). 
Also, in a 30-year follow-up study of 541 child psychiatric inpatients, retrospective 
CGAS ratings at intake based on hospital records did not differ between later convicted 
and non-convicted adults (Mordre et al. 2011).  
A possible explanation for the lack of prognostic information in CGAS ratings at intake 
is that they reflect temporary psychosocial functional impairment caused by the 
symptoms that prompt patients to seek help. By contrast, CGAS ratings at end-of-
treatment are performed when the acute impairment presumably has subsided and thus 
more closely reflects the individual’s usual level of function. This is presumably a more 
informative long-term prognostic marker. For example, those with the lowest mean 
CGAS rating at intake - suicide attempt – were also those also showed the largest mean 
value on CGAS improvement after end-of-treatment (Table 8). The CGAS score at 
intake for the suicidal group is low per definition and hence not representative of the 
child’s level of psychosocial functioning when the risk for suicidal behaviour has 
subsided. Another explanation is that the clinician knows the patient less well at intake, 
which may increase bias and random error. 
There are no previous longitudinal studies evaluating the long-term predictive 
properties of CGAS. However, other studies provide indirect support for the notion that 
CGAS contain prognostic information. Most longitudinal population-based studies 
(Rutter et al. 1976; Kim-Cohen et al. 2003; Olsson et al. 2006; Sourander et al. 2007; 
Pickles et al. 2010) as well as a longitudinal follow-up of child psychiatric patients 
(Engqvist and Rydelius 2007) have found that problems at school, with behaviour, and 
in relationships are correlated with poor outcomes in adulthood.  
7.6 THE CGAS INSTRUMENT 
The most striking observation made when analysing the rating distributions for each 
case vignette was that some CGAS intervals were rarely used, for example the interval 
21-30 (Figure 1). One reason could be that the description of clinical examples in this 
interval was brief and the raters had difficulty recognising their case with this sparse 
information. Also, some intervals contain examples that reflect different levels of care 
intensity. Child psychiatric care has changed since 1983 when the scale was developed. 
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Inpatient resources have decreased and new outpatient units have developed new 
methods for child psychiatric patients and their families. Some examples of care levels 
therefore appear out of date. There were also suicidal cases in the training vignettes that 
created a lot of questions from the participants. This is a problem area where the scale 
has some weaknesses. In the interval 31-40 one of the clinical examples is “suicidal 
attempts with clear lethal intent”. These cases are usually in need of considerable 
supervision, which is rated lower than 21. 
7.7 METHODOLOGICAL CONSIDERATIONS 
There are several methodological facets of these studies to consider. An important first 
strength of this thesis is the large number of research subjects. Paper I and II are based 
on 703 health care professionals, which is considerably more than previous studies. 
Paper III evaluated 12,613 child psychiatric patients. Finally, in Paper IV 4,876 child 
psychiatric patients were followed during 1-1½ years. Second, the randomisation 
procedure used in the CGAS training program is unique. This makes the findings more 
conclusive than those in previous studies of training’s effectiveness. Also, the inclusion 
of the comparison group, albeit non-randomised, allowed a more rigorous evaluation of 
the overall training effects than previous studies. Third, Papers III and IV benefitted 
from the high resolution available in the clinical database Pastill, which comprises a 
large number of clinical variables, including axis I, IV, and V, as well as several 
treatment interventions and ratings of treatment response. Moreover, the high rate of 
registrations in the database Pastill means that almost all child psychiatric patients in 
Stockholm County were captured, making the results highly generalisable. Fourth, the 
linkage to national registers minimized patients lost to follow-up in Paper IV. 
With respect to limitations, it might be argued that although written case vignettes 
(Paper I and II) have been shown to be a valid tool for assessing the quality of clinical 
work, judging written case vignettes is different from assessing real patients. For one 
thing, vignettes provide limited information.(Peabody et al. 2000; Peabody et al. 2004). 
For another, there is a risk that reliability based on vignettes inflates the ICC by 
minimizing information variance that would occur if two raters independently 
interviewed the patient.  
Second, for practical reasons the number of rated cases in Paper I and II was restricted 
to five, which somewhat limits the statistical power. When choosing the number of 
vignettes it was necessary to balance how much time the research project could engage 
the participants and how many cases it was possible to rate without loss of 
concentration and motivation, on the one hand, with the number of cases needed to get 
enough statistical power on the other. With the available time frame it was deemed that 
5 cases balanced these needs. 
Third, Paper I and II examined actual CGAS ratings but did not assess health care 
professionals’ skills in interviewing patients and their families. This is of potential 
importance since we have within CAMHS little systematic knowledge about how much 
a clinician’s professional background, clinical experience, and personality affect the 
quality of the interview and the assessment.  
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Fourth, the comparison group in Paper II was not randomised and was smaller than the 
intervention groups. This study can therefore not be equated with an RCT. Still, the 
inclusion of a comparison group at all was new in terms of training studies and 
highlighted the important question of unspecific training effects. I have not found other 
training studies with randomised control groups and I look forward to conducting new 
training studies comparable to ordinary RCTs. 
Fifth, to check overall training effect there should have been a rating directly after the 
training. This was not done. Instead the follow-up in Paper II occurred twelve months 
after the training. A recently published study suggests that the follow-up period should 
not be longer than three months (Cross et al. 2011). Rater drift is a known 
phenomenon, and in Paper II it could also have influenced the results negatively 
(Muller and Szegedi 2002; Yavorsky et al. 2010).  
Sixth, despite the high rate of registration in Pastill there are missing data with respect 
to clinical and outcome variables. Treatment interventions evaluated in Paper III are 
broadly defined in Pastill without information about the specific psychotherapeutic 
method used. Also, medication information was restricted to whether the drug was a 
central stimulant or other than a central stimulant, and this broad level of information 
limits the interpretation of the results.  
Seventh, formal studies of the validity of most Pastill diagnoses are lacking. However, 
the autism diagnoses have been evaluated and the results showed that 92% of the 
diagnoses in Pastill could be confirmed through an independent retrospective 
evaluation of medical charts (Selma Idrizbegovic, personal communication 2011). The 
diagnostic information in Paper IV on childhood bipolar disorder is included in the 
group “mood disorders” and not further specified in Pastill. Therefore, it is not possible 
to examine if bipolar disorder was diagnosed already during childhood.  
Eight, the registering of CGAS ratings in Pastill was initiated 1 July 2006, which 
resulted in a limited follow-up time period of one to one-and-a-half years in Paper IV. 
This resulted in a relatively low number of outcome events in some rare cases (for 
example schizophrenia).  
Ninth, the CGAS rating at case closure in Paper III and IV was made by a large group 
of clinicians that had access to the first CGAS rating. This might have biased the rater. 
However, the differences in improvement between mental retardation (lowest 
improvement) and suicide attempt or mood disorder (highest improvement) in Paper III 
are in line with clinicians’ general perceptions of how the effectiveness of the different 
treatment options differs between the diagnostic groups. This suggests that the 
clinicians do not rate cases as improved by sheer routine. The validity of the CGAS 
ratings is also supported by the significant correlation between ∆CGAS and the overall 
assessment of treatment response made by the clinician at case closure also described in 
Paper III. 
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8 CONCLUSIONS 
Paper I shows that the inter-rater reliability is moderate when CGAS is used in a large 
heterogeneous clinical setting with no prior training. This suggests that CGAS is a 
useful instrument, but that one should be cautious when comparing CGAS ratings of 
the same patient from different practitioners. The untrained raters differed substantially 
from the experts and tended to rate patients significantly higher, that is less functionally 
impaired. One cannot emphasize too much how important it is to look at the lowest 
level of functioning in the past month. Failure to do this is one factor that may create 
low inter-rater reliability using CGAS. The differences in ratings between professional 
groups raise questions about how and by whom CGAS ratings should be performed to 
be most accurate. Altogether, this stresses the importance of proper training in 
conjunction with the introduction of new rating scales.  
In Paper II, there were no differences between the two forms of training, which speaks 
in favour of using the less resource-demanding CD. However, even though CGAS 
ratings improve with training, the effect was surprisingly small and unlikely to be 
clinically relevant. Intriguingly, there was a similarly positive effect in the non-
randomised comparison group that received no training. These findings call into 
question the usefulness of this type of brief training programme. The findings also 
suggest that future education trials should include regular, randomly assigned control 
groups to control for the unspecific improvement that might occur.  
The naturalistic effectiveness study in Paper III, showed that mean CGAS ratings 
improved after child psychiatric treatment-as-usual on the same order of magnitude as 
in clinical trials, but the level of improvement differed significantly depending on 
diagnosis. Interestingly, and at odds with results from clinical trials, medication in 
mood disorder treatment and central stimulants in ADHD treatment were not positively 
associated with improvement of CGAS ratings. By contrast, several of the different 
psychotherapeutic interventions were positively correlated with ∆CGAS in mood 
disorders. These results raise questions as to the effectiveness of medication in 
naturalistic child psychiatric settings. Further studies are warranted to evaluate the 
effectiveness of medication and psychotherapy in regular clinical settings, especially 
for ADHD and mood disorders. 
The results in Paper IV suggest that CGAS ratings at end-of-treatment - but not at 
intake - provide specific information about the long-term outcome of individuals that 
have been subject to child psychiatric care. Particular attention regarding additional 
interventions or intensified follow-up might be warranted for adolescents with an end-
of-treatment CGAS score of 60 or less. 
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9 IMPLICATIONS FOR THE FUTURE 
9.1 TRAINING 
It is impossible for me not to think that a new training study with a randomised control 
group and follow-up directly after training, and again after three and six months would 
add valuable information to CAMHS using CGAS. 
I also see a potential to improve the training programme after my experience of 
conducting more than 70 seminars and training more than 1,000 clinicians. I would 
primarily emphasise that the ratings should reflect the lowest level of functioning over 
the past month, and emphasize the patient’s impairment. Training might work best if 
tailored to particular professional groups. 
9.2 INDIVIDUAL VS GROUP CGAS RATINGS 
Clinician-rated tools like CGAS are used to operationalize the clinical evaluation. 
However, the process of decision-making is undisclosed; notes and charts seldom 
indicate how the information was collected, interpreted, and merged into the chosen 
index. In daily clinical practice, most CGAS ratings are done individually. It would be 
interesting to study how the decision-making process differs when groups do the 
ratings. There is a possibility that ratings done together with other team members would 
result in more reliable and valid results. Group decision-making is recommended in 
many areas (Surowiecki 2004; Wu et al. 2007), and it has been shown that groups often 
perform intellectual tasks better than the sum of the individuals in a group (Woolley et 
al. 2010).  
9.3 CURRENT CGAS, REVISED CGAS OR A NEW SCALE 
Despite any drawbacks with the scale, there are many advantages to keeping CGAS as 
is. First, it has already been heavily studied and evaluated. Second, it would allow on-
going comparisons between study populations, since CGAS is and has been widely 
used, including in several national registers in the UK and Sweden.  
An alternative is to keep CGAS but revise it in ways that would increase its reliability, 
validity, and clarity for clinicians. The clinical examples, for instance, need to be more 
thoroughly described in some of the intervals so the content is more equally distributed. 
Some levels of care specified in the scale are out-dated and should also be revised. 
Moreover, the different examples concerning suicidality need to be clarified and the 
degree of supervision recommended for different levels needs to be made clearer.  
Another alternative is to create an entirely new rating tool for global assessment of 
children’s psychosocial functioning. This would be demanding, but if it were done, it 
should be based from the start on children’s levels of functioning and not be a version 
of an adult tool merely adapted to children. Ideally a new scale would also remedy 
some of the holes in CGAS, most importantly by including functioning around the 
basic activities of daily living (ADL) including hygiene, getting dressed, food intake, 
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and sleep habits, which are often impaired in children and adolescents with psychiatric 
disorders.  
9.4 TRANSFER TO ADULT PSYCHIATRY 
The increased risk of child psychiatric patients developing adult psychiatric disorders 
also highlights the importance of bridging the gap between child and adult psychiatry – 
an endeavour with well-known challenges. In the UK, for example, less than 25% of 
services have specific arrangements for transfer of care from child to adult psychiatry 
(Audit Commission 1999; Singh et al. 2005). This disrupted continuity of treatment is 
likely to contribute to future psychiatric illness among patients (Singh 2009). With 
CGAS ratings as a basis of information about the long-term health of individuals, the 
transition to adult psychiatry could be individualized and better planned, with more 
attention paid to cases with higher risk for adult psychiatric disorders. Clinical 
evaluations supported by rating tools may foster a better organization for the transfer of 
young vulnerable adolescents to adult psychiatric care. 
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10 EPILOGUE 
Does child psychiatric treatment make a difference? This thesis suggests that child 
psychiatric care can be effective. Moreover, my studies indicate that CGAS can be used 
to help measure psychosocial functioning but that it is not a perfect instrument. Like all 
rating scales, CGAS has advantages and disadvantages.  
I was disappointed that training did not improve the quality of ratings to make CGAS 
an even more valuable and reliable tool, but I have discussed several possible 
explanations for why training did not have the expected effects.  
The most surprising results for me were the predictive properties of CGAS. That CGAS 
scores had such high predictive value indicates that it is a valid tool and that the scale 
can be highly useful for clinicians in their efforts to provide safe and effective care to 
children with mental illness. This finding also confirms my belief that it is important to 
combine clinical evaluation with rating tools and diagnostic instruments, and not to rely 
solely on one method. But my findings also confirm the criticisms levelled at using 
CGAS as the sole indicator of treatment needs or treatment outcomes. For example, 
performing CGAS via a telephone interview with a parent, as sometimes now occurs in 
Sweden, seems ill-advised. Misuse of CGAS ratings may, furthermore, increase the risk 
that professionals lose confidence in the instrument. Evaluation and treatment of 
patients must ultimately rest on clinical judgement that is based on an overall 
assessment of the patient’s diagnosis, psychosocial functioning, level of distress, and 
the effect on family and network.  
There is a genuine interest among CAMHS’ management and health administrators to 
evaluate treatment continuously together with clinicians and researchers, and guarantee 
high quality care throughout the region and the country. In order to do this, my findings 
point to the necessity of more research that evaluates the effectiveness of child 
psychiatric care in the real world and not just within RCTs. 
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